Details of the Drug

General Information of Drug (ID: DMNPZL4)

• Drug Name: Dacarbazine
• Synonyms: Biocarbazin; Biocarbazine; DTIC; DTICDome; DTIE; Dacarbazino; Dacarbazinum; Dacatic; Decarbazine; Deticene; Dimethyltriazenoimidazolecarboxamide; ICDMT; ICDT; Biocarbazine R; DTIC Dome; Dimethyl Imidazole Carboxamide; Dimethyl Triazeno Imidazole Carboxamide; Imidazole carboxamide; HE1150000; Carboxamide (TN); Carboxamide, Dimethyl Imidazole; DIC (TN); DTIC (TN); DTIC-Dome; Dacarbazino [INN-Spanish]; Dacarbazinum [INN-Latin]; Imidazole (TN); Imidazole Carboxamide, Dimethyl; NPFAPI-05; DTIC-Dome (TN); Di-me-triazenoimidazolecarboxamide; Di-methyl-triazenoimidazolecarboxamide; Dtic-Dome (TN); DTIC, DTIC-Dome, Dacarbazine; Dacarbazine (JAN/USP/INN); Dacarbazine [USAN:INN:BAN:JAN]; (5E)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; (Dimethyltriazeno)imidazolecarboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 4(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(3,3-Dimethyl-1-triazeno)imidazole-5-carboxamide; 4-(3,3-Dimethyltriazeno)imidazole-5-carboxamide; 4-(5)-(3,3-Dimethyl-1-triazeno)imidazole-5(4)-carboxamide; 4-(Dimethyltriazeno)imidazole-5-c arboxamide; 4-(Dimethyltriazeno)imidazole-5-carboxamide; 4-(or 5)-(3,3-Dimethyl-1-triazeno)imidazole-5(or 4)-carboxamide; 4-[(1E)-3,3-Dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 4-[3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide; 5(or 4)-(dimethyltriazeno)imidazol e-4(or 5)-carboxamide; 5(or 4)-(dimethyltriazeno)imidazole-4(or 5)-carboxamide; 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)-1H-imidazole-4-carboxamide; 5-(3,3-Dimethyl-1-triazenyl)imidazole-4-carboxamide; 5-(3,3-Dimethyltri azeno)imidazole-4-carboxamide; 5-(3,3-Dimethyltriazeno)-imidazole-4-carbamide; 5-(3,3-Dimethyltriazeno)imidazole-4-carboxamide; 5-(3,3-dimethyltriaz-1-en-1-yl)-1H-imidazole-4-carboxamide; 5-(Dimethyltriazeno)-4-imidazolecarboxamide; 5-(Dimethyltriazeno)imidazole-4-carboxamide; 5-(Dimethyltriazeno)imidazole-4-carboximide; 5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide; 5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Adenocarcinoma	2D40	Approved	[1]
Astrocytoma	2A00.0Y	Approved	[1]
Brain disease	8C70-8E61	Approved	[1]
Central nervous system disease	8A04-8D87	Approved	[1]
Glioblastoma	2A00	Approved	[1]
Gliosarcoma	N.A.	Approved	[1]
Melanoma	2C30	Approved	[2]
Classic Hodgkin lymphoma	N.A.	Investigative	[1]
Neuroblastoma	2D11.2	Investigative	[1]

• Therapeutic Class: Anticancer Agents
• Affected Organisms: Humans and other mammals
• ATC Code:
  L01AX04: Dacarbazine
  L01AX: Other alkylating agents
  L01A: ALKYLATING AGENTS
  L01: ANTINEOPLASTIC AGENTS
  L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 182.18
  Logarithm of the Partition Coefficient (xlogp); -0.6
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption: The drug is unstablely, slowly and incompletely absorbed []
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
  Clearance: The drug present in the plasma can be removed from the body at the rate of 2.6 mL/min/kg [4]
  Elimination: 39% of drug is excreted from urine in the unchanged form [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5 hours [4]
  Metabolism: The drug is metabolized via the hepatic []
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.7 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 1% [4]
  Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.2 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 4.2 mg/mL [3]
• Chemical Identifiers:
  Formula: C6H10N6O
  IUPAC Name: 4-[(E)-dimethylaminodiazenyl]-1H-imidazole-5-carboxamide
  Canonical SMILES: CN(C)/N=N/C1=C(NC=N1)C(=O)N
  InChI: InChI=1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
  InChIKey: FDKXTQMXEQVLRF-ZHACJKMWSA-N
• Cross-matching ID:
  PubChem CID: 135398738
  ChEBI ID: CHEBI:94587
  CAS Number: 4342-03-4
  UNII: 7GR28W0FJI
  DrugBank ID: DB00851
  TTD ID: D0Y7ZU
  INTEDE ID: DR0404
  ACDINA ID: D00979
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Breaker	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[7]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[8]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Baculoviral IAP repeat-containing protein 5 (BIRC5)	OTILXZYL	BIRC5_HUMAN	Gene/Protein Processing	[10]
Clusterin (CLU)	OTQGG0JM	CLUS_HUMAN	Drug Response	[11]
DNA repair nuclease/redox regulator APEX1 (APEX1)	OT53OI14	APEX1_HUMAN	Drug Response	[12]
Erythropoietin (EPO)	OTZ90CN4	EPO_HUMAN	Drug Response	[13]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1)	OT2YYI1A	MCL1_HUMAN	Drug Response	[14]
Interferon regulatory factor 1 (IRF1)	OT43DI6J	IRF1_HUMAN	Gene/Protein Processing	[15]
Interleukin-8 (CXCL8)	OTS7T5VH	IL8_HUMAN	Gene/Protein Processing	[16]
Methylated-DNA--protein-cysteine methyltransferase (MGMT)	OT40A9WH	MGMT_HUMAN	Gene/Protein Processing	[17]
Mitogen-activated protein kinase 1 (MAPK1)	OTH85PI5	MK01_HUMAN	Drug Response	[18]
Mitogen-activated protein kinase 3 (MAPK3)	OTCYKGKO	MK03_HUMAN	Drug Response	[18]

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Bone Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
RPMI-3460/CS1	GDSC2	5.7625	8.0692	3.4689	2.3804
TC71	CTRP2	3.2929	6.5819	2.8793	19.8008
SK-N-MC	CTRP2	3.6281	6.4926	3.2727	17.3612
MHH-ES-1	GDSC2; CTRP2	4.7779	8.1146	3.8285	12.0852
EW-3	GDSC2	4.9112	8.6781	2.6133	9.1844
TC-71	GDSC2	4.932	6.8758	3.5107	3.6099
SK-PN-DW	GDSC2	5.1528	9.9074	2.1878	11.1328
NY	GDSC2	5.2611	11.8928	1.2878	15.8408
ES6	GDSC2	5.3983	8.4784	3.0578	5.3567
EW-13	GDSC2	5.4523	8.6362	3.0185	5.4802
ES7	GDSC2	5.5114	11.2029	1.8154	12.3805
SK-ES-1	GDSC2; CTRP2	5.5924	10.8226	3.2689	12.5345
NOS-1 [Human HNSCC]	GDSC2	5.6302	8.5738	3.1622	4.2941
ES4	GDSC2	5.7399	8.8297	3.1115	4.385
CAL-72	GDSC2	5.7512	10.529	2.3136	8.9963
H-EMC-SS	GDSC2	5.8127	8.7621	3.1869	3.8324
U2OS	GDSC2; CTRP2	5.8377	14.978	1.4042	19.1286
EW-11	GDSC2	5.9279	10.002	2.6828	6.496
HuO-3N1	GDSC2	5.9292	12.7311	1.3699	13.7732
CHSA8926	GDSC2	5.9418	8.2235	3.4984	1.9876
SJSA-1	CTRP2	5.9463	7.7131	4.3657	1.6184
A-673	GDSC2; CTRP2	5.9946	6.9644	5.5423	2.2086
HuO9	GDSC2	6.1025	8.832	3.3209	2.6654
EW-22	GDSC2	6.1612	8.5171	3.4864	1.7796
ES8	GDSC2	6.2513	8.0016	3.7352	0.6796
EW-7	GDSC2	6.2537	8.3462	3.6012	1.1809
EW-24	GDSC2	6.2894	7.8805	3.7965	0.4649
EW-1	GDSC2	6.3144	9.8391	2.9937	4.0745
MG-63	GDSC2; CTRP2	6.415	10.4194	4.1576	7.2415
EW-16	GDSC2	6.4402	10.5142	2.7623	5.1248
CADO-ES1	GDSC2	6.4524	7.8251	3.8787	0.2037
EW-18	GDSC2	6.6559	9.2141	3.439	1.4764
ES5	GDSC2	6.9499	9.8579	3.3167	1.7078
HOS	GDSC2; CTRP2	7.1189	10.0567	4.8475	3.2955
Hs 822.T	CTRP2	7.4141	12.283	3.9797	6.3555
CAL-78	GDSC2; CTRP2	7.8902	9.6581	5.4471	0.515
SW1353	CTRP2	8.0154	13.9528	3.5877	8.1032
G-292 clone A141B1	GDSC2; CTRP2	8.1641	10.329	5.3057	0.7223
Hs 888.T	CTRP2	8.8012	10.3217	5.5583	0.085
SaOS-2	GDSC2; CTRP2	9.8876	19.1092	2.3697	9.1013

Cancer Drug Sensitivity Data Curated from 202 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MEC1	CTRP2	2.4023	4.4124	2.3688	24.3769
JK1	CTRP2	3.153	7.2337	2.4997	21.6113
JM1	CTRP2	1.7957	4.4494	1.726	28.5398
MOLM-16	CTRP2	-1.6402	2.3863	-1.6947	51.1565
MV4-11	CTRP2	-0.8328	1.0643	-0.8334	45.8182
SEM	CTRP2	-0.4684	1.3408	-0.469	43.3909
NALM-6	GDSC2; CTRP2	-0.1383	1.4637	-0.1386	41.1907
SKM-1	GDSC2; CTRP2	0.111	1.5157	0.1109	39.5296
KMS-12-BM	GDSC2; CTRP2	0.1528	2.2543	0.1487	39.2638
P31/FUJ	CTRP2	0.6876	5.6953	0.2899	42.2229
OCI-AML-2	GDSC2; CTRP2	0.9248	2.4046	0.9241	34.1097
EoL-1	GDSC2; CTRP2	0.9846	2.0664	0.9845	33.7094
KE-37	GDSC2; CTRP2	1.0627	2.5218	1.062	33.1912
RS4;11	GDSC2; CTRP2	1.224	6.7749	0.3013	30.5439
OCI-Ly3	CTRP2	1.2243	3.8419	1.1833	32.2483
MOLT-16	GDSC2; CTRP2	1.2705	3.5377	1.2505	31.8708
A4/Fukuda	GDSC2; CTRP2	1.2719	5.668	0.9338	32.889
BV-173	CTRP2	1.3064	3.9618	1.2593	31.722
NOMO-1	GDSC2; CTRP2	1.3901	6.3806	0.8694	32.6836
DB	GDSC2; CTRP2	1.4761	5.7574	1.1342	31.5626
PL21	CTRP2	1.6221	5.1683	1.4261	30.1194
P12-Ichikawa	GDSC2; CTRP2	1.6898	4.0132	1.6559	29.1243
Mino	CTRP2	1.7395	4.3419	1.6786	28.8844
AML-193	CTRP2	1.7959	6.3819	1.3115	29.931
KE-97	CTRP2	1.8197	4.6083	1.7318	28.4418
OCI-Ly10	CTRP2	1.8906	7.1863	1.155	30.1333
RPMI-8402	CTRP2	1.9725	4.1161	1.9429	31.4547
SIG-M5	CTRP2	2.0512	3.2644	2.0504	26.6056
NB4	CTRP2	2.1044	3.9682	2.0883	26.3028
KM-H2	GDSC2; CTRP2	2.1888	5.9269	1.8682	28.7594
Karpas-299	GDSC2; CTRP2	2.2233	5.8263	1.9318	26.4587
JURL-MK1	GDSC2; CTRP2	2.25	5.2195	2.096	25.8042
EM-2	GDSC2; CTRP2	2.3104	4.5667	2.2577	25.054
SUP-T1	GDSC2; CTRP2	2.3206	4.9454	2.2192	25.1527
HEL	GDSC2; CTRP2	2.3279	5.207	2.1826	27.1251
Reh	GDSC2; CTRP2	2.3463	4.8092	2.2664	24.9078
WSU-DLCL2	CTRP2	2.4311	5.1667	2.3013	24.515
HH [Human lymphoma]	GDSC2; CTRP2	2.5057	10.4914	0.4606	30.324
Kasumi-2	CTRP2	2.5575	6.994	1.9431	25.3874
LC4-1	GDSC2	2.5595	5.6938	1.9058	21.2929
KMS-21-BM	CTRP2	2.5618	6.706	2.0445	25.0147
CMK	CTRP2	2.5753	4.8889	2.5	23.3666
Jurkat	GDSC2; CTRP2	2.6459	4.8863	2.4682	19.2006
HEL 92.1.7	CTRP2	2.6585	4.6542	2.6158	22.7012
BL-70	CTRP2	2.6693	4.1974	2.6585	22.5214
CML-T1	GDSC2; CTRP2	2.7176	4.4289	2.6962	22.2353
Karpas-422	GDSC2; CTRP2	2.7367	7.3034	2.0267	24.5528
MC116	CTRP2	2.7615	3.813	2.7605	21.8745
RPMI-8226	GDSC2; CTRP2	2.8057	5.6454	2.6103	22.2513
MHH-CALL-3	CTRP2	2.8133	4.2012	2.8057	21.5515
PF-382	GDSC2; CTRP2	2.8186	6.0316	2.5274	22.5058
SU-DHL-10	GDSC2; CTRP2	2.834	4.447	2.8158	21.4491
KYO-1	CTRP2	2.8515	7.2609	2.1657	23.7134
EB1	CTRP2	2.8762	5.2457	2.7676	21.4774
RPMI-6666	GDSC2; CTRP2	2.9014	6.7391	2.4024	22.7066
REC-1	CTRP2	2.9293	4.9635	2.8674	20.9631
LAMA-84	GDSC2; CTRP2	2.9426	9.5502	1.324	28.1861
JVM-3	GDSC2; CTRP2	3.0554	6.7032	2.5814	21.5965
HT	CTRP2	3.116	5.0331	3.0572	22.7695
L-540	GDSC2; CTRP2	3.1209	5.7155	2.9374	20.1114
JeKo-1	CTRP2	3.1271	5.553	2.9801	19.9412
A3/Kawakami	GDSC2; CTRP2	3.2864	5.2402	3.2098	18.6351
Namalwa	GDSC2; CTRP2	3.4304	6.0044	3.2025	18.2109
DND-41	GDSC2; CTRP2	3.4469	5.9741	3.2286	18.0665
SUP-B15	GDSC2; CTRP2	3.487	6.0929	3.24	17.9031
HPB-ALL	CTRP2	3.5111	7.4461	2.8016	19.4618
Pfeiffer	CTRP2	3.5453	6.6833	3.1193	18.1724
NU-DUL-1	CTRP2	3.5734	5.8149	3.4067	17.0399
THP-1	CTRP2	3.5993	8.5342	2.4431	20.5756
MOLM-13	GDSC2; CTRP2	3.6844	6.2592	3.4072	16.7004
JJN-3	GDSC2; CTRP2	3.8522	7.3646	3.1961	17.0096
CA46	GDSC2; CTRP2	3.9334	7.8113	3.0987	17.1621
MOLM-6	CTRP2	3.9912	8.7701	2.7394	18.403
Peer	CTRP2	4.021	7.3994	3.3607	18.3765
ST486	GDSC2; CTRP2	4.0959	7.5049	3.3964	15.5692
P3HR-1	CTRP2	4.1225	9.1359	2.7048	18.1996
RPMI-8866	GDSC2	4.2246	5.6314	3.5844	4.9607
KCL-22	GDSC2; CTRP2	4.2421	7.6564	3.4857	14.8285
SR	GDSC2; CTRP2	4.2498	5.7344	4.161	12.2613
Ku812	GDSC2; CTRP2	4.2812	9.1065	2.8762	17.1277
Granta-519	GDSC2; CTRP2	4.3557	7.6571	3.6033	14.0657
BE-13	GDSC2	4.4287	6.8477	3.1469	7.134
Ci-1	CTRP2	4.4395	7.4895	3.7618	13.222
NCO2	CTRP2	4.4721	11.1461	2.0884	19.6934
U-698-M	GDSC2	4.5306	6.5301	3.3865	5.3429
MOLT-13	GDSC2; CTRP2	4.5432	7.0057	4.071	11.7388
TALL-1 [Human adult T-ALL]	CTRP2	4.5537	7.4355	3.9034	12.3629
U-937	CTRP2	4.6178	7.7558	3.8296	12.4868
P32/ISH	GDSC2	4.6428	6.1778	3.6459	3.4328
MM1.S	GDSC2; CTRP2	4.653	6.8888	4.234	10.808
SU-DHL-8	GDSC2; CTRP2	4.697	8.4067	3.613	13.154
M-07e	CTRP2	4.7567	11.7596	2.0536	19.1529
SU-DHL-5	GDSC2	4.7676	6.1912	3.7275	2.648
K-562	GDSC2; CTRP2	4.7801	7.2816	4.2039	10.5825
BC-1	GDSC2	4.8393	6.643	3.5592	3.5161
Raji	GDSC2; CTRP2	4.8777	6.8123	4.5024	9.155
SUP-M2	GDSC2; CTRP2	4.9198	7.4039	4.2938	9.8625
Jiyoye	GDSC2	4.9399	7.1907	3.3643	4.4847
ALL-SIL	GDSC2; CTRP2	4.9679	9.0081	3.5916	12.5886
KMS-26	CTRP2	4.9934	7.7869	4.1942	10.0758
Daudi	GDSC2; CTRP2	5.0032	7.9913	4.109	10.3961
KMM-1	CTRP2	5.004	8.1756	4.0232	12.4087
L-363	GDSC2; CTRP2	5.0278	6.5665	4.7588	7.7543
EHEB	CTRP2	5.0362	12.7201	1.8331	21.9557
Ri-1	CTRP2	5.0654	9.6487	3.373	13.2563
RCH-ACV	CTRP2	5.0749	12.1858	2.1326	18.1353
TF-1	CTRP2	5.0924	8.527	3.9418	10.8638
Ki-JK	CTRP2	5.095	9.194	3.6222	14.0436
H9	GDSC2	5.0979	7.2943	3.4221	3.7968
IM-9	GDSC2	5.1096	6.802	3.6606	2.3749
DoHH2	GDSC2; CTRP2	5.1269	6.55	4.8708	8.1441
SU-DHL-1	CTRP2	5.1782	7.0446	4.7169	8.6804
MHH-CALL-4	CTRP2	5.1787	7.143	4.6737	7.6841
SU-DHL-6	GDSC2; CTRP2	5.2018	8.0853	4.2582	9.3096
HL-60	GDSC2; CTRP2	5.2104	9.2383	3.7084	11.5514
L-1236	GDSC2	5.2388	9.554	2.4251	9.515
SCC-3	GDSC2	5.2744	10.1896	2.1391	11.1161
ALL-PO	GDSC2	5.2778	7.9627	3.2232	4.6172
Kasumi-1	GDSC2; CTRP2	5.2783	7.8105	4.4631	8.29
MEG-01	GDSC2	5.285	7.6722	3.3653	3.7618
MHH-CALL-2	GDSC2	5.2894	7.2103	3.5822	2.5064
DEL	GDSC2; CTRP2	5.2921	6.8011	4.9404	6.3317
KMS-11	CTRP2	5.3219	9.6929	3.5878	11.8006
HAL-01	GDSC2	5.3724	11.8898	1.3738	15.1085
ML-2	GDSC2	5.3903	7.1444	3.6701	1.8664
MLMA	GDSC2	5.4294	7.2846	3.63	2.0213
RL	CTRP2	5.4628	7.4282	4.8234	6.3775
WSU-NHL	GDSC2	5.4847	11.1982	1.7981	12.5409
SU-DHL-4	CTRP2	5.5148	7.4388	4.8683	6.0703
MOTN-1	CTRP2	5.5602	7.528	4.8685	5.9642
OPM-2	GDSC2; CTRP2	5.6006	9.4765	3.9458	9.7137
JVM-2	GDSC2; CTRP2	5.6067	9.1669	3.4309	6.6737
Farage	GDSC2	5.664	7.6093	3.616	1.7639
KY821	GDSC2	5.6722	7.5851	3.6307	1.6802
F-36P	CTRP2	5.7042	10.912	3.3216	12.0865
VL51	GDSC2	5.7059	7.9709	3.4809	2.4
EJM	GDSC2; CTRP2	5.7474	10.1137	3.7572	10.1949
ATN-1	GDSC2	5.7528	7.6715	3.6357	1.5556
BL-41	GDSC2	5.7896	7.1636	3.8593	0.5732
RC-K8	GDSC2	5.8131	7.5263	3.7259	1.0781
DG-75	GDSC2	5.8397	8.4948	3.3234	3.038
KOPN-8	GDSC2	5.8626	7.4589	3.7761	0.8258
WIL2 NS	GDSC2	5.8824	8.0337	3.5486	1.817
GR-ST	GDSC2	5.8894	11.8452	1.773	11.7277
SET-2	CTRP2	5.9175	6.9052	5.5041	2.5284
Loucy	GDSC2	5.926	7.9233	3.6172	1.4417
Karpas-1106P	GDSC2	5.9326	7.6545	3.7301	0.9477
MOLP-8	GDSC2; CTRP2	5.9417	7.5823	5.1883	3.8016
L-428	GDSC2; CTRP2	5.9665	9.1608	4.4208	6.9758
KMS-18	CTRP2	6.0395	9.2312	4.4469	6.724
Karpas-231	GDSC2	6.0548	7.4288	3.8692	0.381
KHM-1B	CTRP2	6.0707	9.3225	4.4272	6.7465
KMS-34	CTRP2	6.0993	7.858	5.1829	3.5165
MN-60	GDSC2	6.1111	8.1867	3.5986	1.3287
KG-1	GDSC2	6.1133	7.8747	3.7245	0.8179
HuNS1	CTRP2	6.1231	8.2515	5.0057	4.2163
Hs 445	GDSC2	6.1418	7.7499	3.7848	0.5869
HD-MY-Z	CTRP2	6.1572	10.3177	4.0011	8.3692
OCI-Ly19	CTRP2	6.1626	7.7357	5.2951	2.9287
LP-1	GDSC2; CTRP2	6.1729	9.554	4.3955	6.686
ME1	GDSC2	6.2125	7.62	3.8614	0.3275
SUP-HD1	GDSC2; CTRP2	6.2204	8.4956	4.9622	4.2202
TK [Human B-cell lymphoma]	GDSC2	6.2302	7.7629	3.8161	0.4399
CTV-1	GDSC2	6.2324	10.4191	2.6802	5.9391
MHH-PREB-1	GDSC2	6.2515	7.5473	3.9021	0.2204
U266B1	GDSC2; CTRP2	6.2611	9.505	4.4912	6.1221
EB2	GDSC2	6.2799	7.892	3.7884	0.4936
OCI-M1	GDSC2; CTRP2	6.3364	7.5032	5.5417	1.6114
KO52	CTRP2	6.3692	11.2522	3.706	9.205
TUR	GDSC2	6.3852	8.3382	3.6632	0.8351
ARH-77	GDSC2	6.3873	7.8198	3.8564	0.2698
MOLT-4	GDSC2	6.4457	7.9401	3.8357	0.2942
Ramos.2G6.4C10	GDSC2	6.4481	7.6874	3.9245	0.129
HuT 78	CTRP2	6.4922	9.993	4.4297	5.9698
GA-10	GDSC2	6.5217	8.0413	3.8283	0.2826
NU-DHL-1	CTRP2	6.5291	11.9531	3.4836	9.8331
697	GDSC2	6.5293	8.0642	3.8231	0.2913
HDLM-2	GDSC2; CTRP2	6.5388	12.1408	3.3978	10.1677
JSC-1	GDSC2	6.5488	8.9061	3.513	1.2726
HC-1	GDSC2	6.5567	8.2492	3.7671	0.4136
P30/OHK	GDSC2	6.5581	8.194	3.7876	0.3618
NCI-H929	GDSC2; CTRP2	6.6455	11.9909	3.5561	9.3287
KMOE-2	GDSC2	6.6928	8.521	3.7215	0.4697
SUP-T11	CTRP2	6.7589	8.6821	5.2629	2.1346
BALL-1	GDSC2	6.7623	8.1879	3.8647	0.1496
Hs 611.T	CTRP2	6.7756	8.9628	5.1404	2.5986
CESS	GDSC2	6.7767	8.5387	3.7475	0.3683
Karpas-45	GDSC2	6.8797	8.8204	3.6856	0.4767
KMS-27	CTRP2	6.9445	9.9256	4.793	3.7553
Mono-Mac-1	CTRP2	7.013	11.087	4.2777	5.7502
CCRF-CEM	GDSC2	7.0526	8.8461	3.7419	0.2838
GDM-1	GDSC2; CTRP2	7.0959	9.3755	5.1522	2.1404
Karpas-620	GDSC2; CTRP2	7.1694	11.1421	4.3613	5.174
ME1	CTRP2	7.202	9.1634	5.3113	1.4373
AMO1	GDSC2; CTRP2	7.2407	8.6778	5.5405	0.6489
VAL	GDSC2	7.3235	9.1369	3.7391	0.2152
KMS-20	CTRP2	7.41	11.7241	4.2463	5.2902
OCI-AML-5	GDSC2; CTRP2	7.7211	8.9064	5.6585	0.1571
MOLP-2	CTRP2	7.7899	11.5652	4.5676	3.5364
OCI-AML-3	GDSC2; CTRP2	7.7911	9.1797	5.5867	0.2574
SK-MM-2	GDSC2; CTRP2	8.136	9.8875	5.4635	0.3718
KMS-28BM	CTRP2	8.2703	10.5792	5.2547	0.795

Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Oesophagus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TE15	CTRP2	5.8462	18.7507	-0.4747	24.7648
TE8	CTRP2	7.3653	10.5158	4.7903	3.2005
TE-15	GDSC2	5.063	7.7789	3.1653	5.4265
TE-8	GDSC2	5.639	9.6007	2.6831	7.0793
TE-6	GDSC2; CTRP2	5.9839	10.7378	2.9377	7.6972
OE33	GDSC2; CTRP2	6.0181	7.3419	5.3736	2.8706
TE-11	CTRP2	6.2544	11.3246	3.5772	9.9512
KYSE-270	GDSC2	6.4435	12.3831	1.8927	9.8871
OE21	GDSC2; CTRP2	6.4642	9.6289	4.5889	5.3539
KYSE-70	GDSC2; CTRP2	6.6553	9.0274	5.0263	3.2345
TE-5	GDSC2; CTRP2	6.7827	9.8796	4.7018	4.3677
TE-9	GDSC2; CTRP2	6.8598	10.2607	4.5711	4.7846
OE19	GDSC2; CTRP2	6.9282	8.3277	5.528	0.9458
KYSE-140	GDSC2; CTRP2	6.959	12.3662	3.6095	8.5739
KYSE-30	CTRP2	7.1979	9.2301	5.2792	1.5562
KYSE-510	GDSC2; CTRP2	7.2059	12.6989	3.6285	8.0953
TE-14	CTRP2	7.348	9.3476	5.311	1.298
TE-10	CTRP2	7.4603	14.2028	3.0766	9.8969
TE-1	GDSC2; CTRP2	7.589	12.6753	3.9112	6.3754
KYSE-150	CTRP2	7.6794	9.2037	5.5314	0.4184
KYSE-180	GDSC2; CTRP2	7.9511	9.5648	5.5084	0.3518
KYSE-520	GDSC2; CTRP2	8.1137	15.641	2.842	9.7971
EC-GI-10	GDSC2; CTRP2	8.1992	10.0641	5.4232	0.4298
TE-4	GDSC2; CTRP2	8.3671	9.9325	5.537	0.1788
COLO 680N	GDSC2; CTRP2	8.7891	15.1482	3.5259	6.2711
KYSE-450	GDSC2; CTRP2	8.7916	13.9103	4.0965	4.1537
KYSE-410	GDSC2; CTRP2	9.4012	17.762	2.6912	8.5774

Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Pancreas Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
N2a-PK1	CTRP2	7.2899	10.1871	4.8962	2.8853
SW1990	CTRP2	5.058	10.8355	2.7842	15.6501
BxPC-3	GDSC2; CTRP2	5.3026	12.4174	2.2204	18.481
PSN1	GDSC2; CTRP2	5.6965	7.7975	4.8633	5.6794
HuP-T4	GDSC2; CTRP2	6.1535	14.7037	1.8053	17.0818
Hs 766T	CTRP2	6.2485	8.8282	4.8187	4.7714
PaTu 8988s	CTRP2	6.2552	10.0299	4.2245	7.2508
DAN-G	GDSC2; CTRP2	6.3768	8.225	5.2172	2.8858
PL4	GDSC2	6.4472	8.3274	3.6938	0.6882
Capan-2	GDSC2; CTRP2	6.6257	8.9946	5.0212	3.3001
TCC-Pan2	CTRP2	6.6362	11.2494	3.9172	7.8541
Panc 04.03	CTRP2	6.7022	8.1574	5.4728	1.3905
YAPC	GDSC2; CTRP2	6.7356	9.8482	4.6832	4.5174
AsPC-1	GDSC2; CTRP2	6.8301	10.6113	4.3781	5.6246
Panc 03.27	CTRP2	6.9148	12.4026	3.5583	8.8567
QGP-1	GDSC2; CTRP2	6.9288	10.3398	4.5817	5.3552
PK-45H	CTRP2	6.9383	12.3924	3.5811	8.7242
HPAF-II	GDSC2; CTRP2	6.9488	9.5099	4.995	2.9402
Panc 02.03	GDSC2; CTRP2	7.0345	12.5707	3.5651	8.63
KP-4	GDSC2; CTRP2	7.0789	10.3813	4.6658	4.076
KP-2	GDSC2; CTRP2	7.0811	9.6798	5.001	2.7418
MIA PaCa-2	GDSC2; CTRP2	7.1344	8.4672	5.5756	0.6201
KP-1N	GDSC2	7.1871	9.107	3.7	0.3242
PK-59	CTRP2	7.2698	14.2864	2.8947	10.9227
PaTu 8988t	GDSC2; CTRP2	7.2958	8.4049	5.6738	0.2706
Panc 08.13	GDSC2; CTRP2	7.3327	11.9352	4.0913	6.0252
HPAC	GDSC2; CTRP2	7.3363	9.4666	5.2522	1.5123
Capan-1	GDSC2; CTRP2	7.3527	10.7127	4.6897	3.6085
CFPAC-1	GDSC2; CTRP2	7.3655	9.2543	5.3608	1.2887
Panc 10.05	GDSC2; CTRP2	7.4032	9.4037	5.3163	1.2302
Panc 05.04	CTRP2	7.4345	11.0778	4.5705	3.9693
HuP-T3	GDSC2; CTRP2	7.4355	11.3658	4.4346	4.5041
SNU-213	CTRP2	7.4947	8.7011	5.6446	0.2909
SU.86.86	GDSC2; CTRP2	7.4956	12.2054	4.0733	5.8609
KP-3	GDSC2; CTRP2	7.7486	11.1929	4.7136	3.0343
SUIT-2	GDSC2; CTRP2	7.7724	9.0605	5.6229	0.1997
PaTu 8902	GDSC2; CTRP2	8.2073	9.4635	5.6417	0.0857
L3.3	CTRP2	8.9376	14.2801	4.0147	4.2925

Cancer Drug Sensitivity Data Curated from 60 Cell Line(s) in Skin Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SH4	CTRP2	7.0397	9.5136	4.1721	1.2615
LOX-IMVI	GDSC2; CTRP2	3.1341	7.8707	2.2337	22.6466
WM88	CTRP2	4.097	8.6134	2.917	17.4374
IPC-298	CTRP2	5.045	9.0337	3.6527	12.159
WM1552C	GDSC2	5.0972	7.1242	3.5022	3.3212
GAK	GDSC2	5.3866	7.1345	3.6725	1.8592
G-mel	GDSC2	5.4634	8.5865	3.0494	5.274
HMV-II	GDSC2	5.9313	9.9621	2.7038	6.3688
WM278	GDSC2	6.0254	8.0249	3.6237	1.3068
Hs 934.T	CTRP2	6.2196	11.6147	3.4039	10.7316
CP66-MEL	GDSC2	6.2358	7.5888	3.8815	0.2701
WM793	GDSC2; CTRP2	6.2701	9.6064	4.4478	6.2874
M14	GDSC2	6.2851	9.4097	3.1678	3.1978
WM983B	CTRP2	6.3005	10.1717	4.1901	7.3119
COLO 679	GDSC2	6.3206	8.2262	3.6785	0.8281
COLO 829	GDSC2; CTRP2	6.3229	9.6878	4.4493	6.1858
Hs 294T	CTRP2	6.3304	11.0392	3.7811	8.9643
A2058	GDSC2; CTRP2	6.4257	7.8978	5.413	2.0022
SH-4	GDSC2	6.4298	8.4384	3.6438	0.8717
WM35	GDSC2	6.5475	11.9504	2.1646	8.2094
Mel Ho	CTRP2	6.5496	10.8306	4.0582	7.4187
Mel JuSo	GDSC2; CTRP2	6.5682	9.1938	4.882	3.9631
A101D	GDSC2; CTRP2	6.5852	9.5917	4.6988	4.6941
IGR-39	CTRP2	6.7292	9.8396	4.6828	4.5292
IGR-37	GDSC2; CTRP2	6.7535	8.482	5.3537	1.786
WM115	GDSC2; CTRP2	6.7562	10.9842	4.1397	6.7292
K029AX	CTRP2	6.7991	11.3612	3.9858	7.2942
MeWo	CTRP2	6.8192	10.6388	4.3565	5.7308
A-375	GDSC2; CTRP2	6.8584	10.3923	4.5059	5.0545
MDA-MB-435S	CTRP2	6.8804	10.7463	4.3486	5.6662
CHL-1	GDSC2	6.9517	9.3644	3.5118	0.9615
UACC-62	GDSC2; CTRP2	6.9888	9.7114	4.9256	3.1617
SK-MEL-30	CTRP2	6.9979	8.6922	5.4054	1.3095
WM266-4	CTRP2	7.1325	10.3148	4.7338	3.7287
SK-MEL-5	GDSC2; CTRP2	7.1431	9.0225	5.3407	1.3923
UACC-257	GDSC2; CTRP2	7.2679	11.335	4.3362	5.1319
G-361	GDSC2; CTRP2	7.3033	11.253	4.3998	4.8258
WM1799	CTRP2	7.3183	11.872	4.1118	5.9637
RVH-421	CTRP2	7.3552	12.241	3.9588	6.5269
Hs 895.T	CTRP2	7.3819	11.5444	4.3134	5.0611
RPMI-7951	GDSC2; CTRP2	7.3923	9.1301	5.4273	0.8807
SK-MEL-28	CTRP2	7.3928	8.2964	5.7517	0.1013
HMCB	CTRP2	7.4078	10.9661	4.6059	3.8655
IGR-1	GDSC2; CTRP2	7.4114	10.1722	4.9779	2.4306
Hs 688(A).T	CTRP2	7.421	8.5149	5.6839	0.2025
SK-MEL-3	CTRP2	7.4313	11.6057	4.3174	4.9761
SK-MEL-2	GDSC2; CTRP2	7.4594	8.3853	5.7451	0.096
CJM [Human melanoma]	CTRP2	7.5347	8.8447	5.6071	0.3135
Hs 852.T	CTRP2	7.5662	9.3511	5.4212	0.7734
Hs 936.T	CTRP2	7.6217	11.1336	4.6633	3.3733
SK-MEL-24	GDSC2; CTRP2	7.6727	11.1659	4.6798	3.2495
COLO 800	CTRP2	7.7736	15.7715	2.5359	11.4836
Hs 940.T	CTRP2	7.8279	9.7166	5.3962	0.6774
SK-MEL-31	CTRP2	7.8642	9.2441	5.592	0.2247
WT2-iPS	GDSC2; CTRP2	7.9514	9.0709	5.6852	0.0795
Hs 839.T	CTRP2	8.0248	12.8763	4.1041	5.025
SK-MEL-1	CTRP2	8.0353	9.2996	5.6366	0.1186
HT-144	GDSC2; CTRP2	8.7608	15.9162	3.1472	7.7307
Hs 944.T	CTRP2	8.7723	17.875	2.2192	11.1347
COLO 792	GDSC2; CTRP2	9.24	18.7402	2.1217	10.8207

Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Aero Dig Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ESO-26	GDSC2	4.9488	7.0344	3.4459	3.9671
OACP4 C	GDSC2	5.2913	7.2012	3.5875	2.4734
KYSE-220	GDSC2	5.646	7.8566	3.498	2.3985
ESO-51	GDSC2	5.7197	9.0025	3.0186	4.9557
TE-12	GDSC2	5.7592	11.5546	1.8222	11.7569
OACM5.1 C	GDSC2	5.7963	8.3485	3.3641	2.8864
FLO-1	GDSC2	5.8866	9.1622	3.0481	4.4844
KYSE-50	GDSC2	6.3846	12.8304	1.6397	11.3551
KYAE-1	GDSC2	6.8424	8.3219	3.8473	0.1581
SK-GT-4	GDSC2	7.0766	15.6293	0.7665	14.1896

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
COLO 684	GDSC2	5.4132	8.8572	2.8866	6.3482

Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Autonomic Ganglia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KP-N-SI9s	CTRP2	2.3074	5.6762	2.0604	25.7455
CHP-212	GDSC2; CTRP2	4.1644	6.6576	3.7977	13.8444
Kelly	GDSC2; CTRP2	4.349	6.5487	4.0355	12.4204
MHH-NB-11	CTRP2	4.8011	23.3613	-3.6708	33.2301
NH-12	GDSC2	5.2847	7.2692	3.5524	2.6824
CHP-134	GDSC2	5.5346	9.2873	2.7627	6.8288
SiMa	GDSC2	5.7066	9.5107	2.7709	6.4241
IMR-5	GDSC2	5.7155	10.3278	2.386	8.6551
SJNB-14	GDSC2	5.7897	7.5822	3.6916	1.2536
SK-N-AS	GDSC2; CTRP2	6.2839	9.7815	4.3715	6.5825
SJNB-10	GDSC2	6.2961	8.2746	3.6489	0.9564
SJNB-13	GDSC2	6.2961	8.4555	3.5769	1.2415
SK-N-SH	CTRP2	6.3331	9.6879	4.4573	6.1338
NB1	CTRP2	6.3473	7.9138	5.3486	2.3896
SJNB-7	GDSC2	6.4397	8.2752	3.7104	0.6393
TGW	GDSC2	6.5784	8.4088	3.7172	0.5392
KP-N-YN	GDSC2	6.5916	9.068	3.4679	1.4169
CHP-126	CTRP2	6.6296	9.0273	5.008	3.3483
NB69	GDSC2	6.7285	8.6416	3.6914	0.5341
NB(TU)1	GDSC2	6.7374	8.5107	3.7425	0.3963
GOTO	GDSC2	6.8066	8.7981	3.6649	0.5685
SK-N-DZ	GDSC2; CTRP2	6.8357	8.8545	5.2314	2.1579
SK-N-BE(2)-M17	GDSC2	6.9485	8.7683	3.7306	0.3416
SK-N-FI	CTRP2	7.2391	8.8918	5.4499	0.9314
GI-ME-N	GDSC2	7.4225	9.7293	3.5672	0.5358
NH-6	CTRP2	8.1312	9.5247	5.5931	0.1545
SK-N-BE(2)	CTRP2	8.4191	10.1538	5.4779	0.2536

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Biliary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-478	CTRP2	5.7145	11.1344	3.2195	12.4837
SNU-1079	CTRP2	5.9439	8.9584	4.5028	6.6764
SNU-1196	CTRP2	6.3304	12.8703	2.8668	12.6989
HuCC-T1	GDSC2; CTRP2	6.5861	10.2006	4.3986	5.9393
SNU-869	CTRP2	7.1096	9.6484	5.0339	2.5778
SNU-308	CTRP2	7.3319	10.807	4.6316	3.8641
HuH-28	CTRP2	7.734	9.2166	5.5497	0.3533
SNU-245	CTRP2	8.1238	10.4616	5.2341	0.9391

Cancer Drug Sensitivity Data Curated from 84 Cell Line(s) in Breast Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
DU4475	GDSC2; CTRP2	2.0985	3.8205	2.0883	26.3222
Evsa-T	GDSC2	4.5814	6.5295	3.4262	4.9605
MDA-MB-453	GDSC2; CTRP2	4.9447	8.1981	3.9546	11.1647
CAL-148	CTRP2	4.9913	7.3314	4.3989	9.2603
MDA-MB-436	GDSC2	5.1447	9.6549	2.3062	10.4537
MFM-223	GDSC2	5.4003	8.6928	2.9567	5.9562
MDA-MB-330	GDSC2	5.6617	9.6834	2.6588	7.1748
HCC2157	GDSC2	5.8458	7.7521	3.6487	1.3867
MDA-MB-468	GDSC2; CTRP2	6.2199	11.2249	3.5989	9.9262
Hs 578T	GDSC2	6.2892	8.3333	3.6226	1.0636
HCC1569	GDSC2	6.3891	9.4165	3.2212	2.7817
HCC1187	GDSC2	6.4913	8.2484	3.7415	0.5155
HMC-1-8	CTRP2	6.5539	8.3461	5.2856	2.33
SK-BR-3	CTRP2	6.5778	9.485	4.7459	4.5109
HCC1806	GDSC2; CTRP2	6.678	8.8876	5.1099	2.8603
MRK-nu-1	GDSC2	6.7004	8.0833	3.8785	0.1426
EFM-19	GDSC2	6.7426	9.3917	3.4079	1.524
HCC1428	GDSC2; CTRP2	6.7514	9.1913	5.0141	3.1415
OCUB-M	GDSC2	6.7837	9.1558	3.5198	1.0546
HCC70	GDSC2	6.8706	13.4824	1.6517	10.3054
COLO 824	GDSC2	6.8968	8.7279	3.7255	0.3723
JIMT-1	GDSC2; CTRP2	7.0353	10.4385	4.6083	4.3705
CAL-51	GDSC2; CTRP2	7.0565	10.1764	4.7489	3.7739
ZR-75-1	CTRP2	7.0862	10.4037	4.66	4.0887
MDA-MB-231	GDSC2; CTRP2	7.0924	9.8754	4.9161	3.0603
MDA-MB-157	GDSC2; CTRP2	7.259	9.2244	5.3162	1.364
HCC1954	GDSC2; CTRP2	7.266	11.3332	4.3358	5.1365
KPL-1	CTRP2	7.281	8.1278	5.7696	0.1017
EFM-192A	GDSC2; CTRP2	7.3149	10.9307	4.5617	4.1637
Hs 578Bst	CTRP2	7.3881	10.2947	4.9073	2.7235
BT-20	GDSC2; CTRP2	7.4387	9.4342	5.322	1.1804
BT-549	GDSC2; CTRP2	7.4484	10.1453	5.0122	2.2616
ZR-75-30	GDSC2; CTRP2	7.4662	10.5937	4.8172	2.9733
CAL-120	GDSC2; CTRP2	7.5395	9.2558	5.4474	0.7159
T-47D	GDSC2; CTRP2	7.6233	10.5858	4.9155	2.4258
HCC38	GDSC2; CTRP2	7.6884	10.6723	4.9144	2.3601
BT-474	GDSC2; CTRP2	7.8087	8.9473	5.6767	0.1128
HCC1419	GDSC2; CTRP2	7.8928	9.8963	5.3542	0.7517
AU565	GDSC2; CTRP2	8.0289	12.379	4.3385	4.1209
CAL-85-1	GDSC2; CTRP2	8.0909	14.2054	3.5176	7.2195
HCC202	CTRP2	8.1103	10.4296	5.2407	0.9292
MDA-MB-361	GDSC2; CTRP2	8.1185	10.2674	5.3095	0.9479
HCC1500	GDSC2; CTRP2	8.1952	9.8824	5.4892	0.3017
HDQ-P1	GDSC2; CTRP2	8.2211	10.101	5.4184	0.431
MCF-7	GDSC2; CTRP2	8.5234	10.1248	5.5271	0.1839
CAMA-1	GDSC2; CTRP2	8.6311	17.5021	2.3017	12.5043
HCC1937	GDSC2; CTRP2	8.6487	10.5564	5.4212	0.2811
MDA-MB-415	GDSC2; CTRP2	8.6527	10.3979	5.4791	0.1948
HCC1395	CTRP2	8.8141	14.6172	3.7874	5.2646
HCC1143	GDSC2; CTRP2	9.2137	17.7096	2.5945	9.1708
BT 145	CTRP2	6.2173	10.0829	4.1674	7.5604
BT 286	CTRP2	6.4708	8.8304	4.9888	3.679
BT164	CTRP2	6.479	7.9736	5.4136	1.9207
BT 179	CTRP2	6.5622	8.1396	5.3906	1.8949
BT 239	CTRP2	6.6641	8.811	5.1373	2.7698
BT 112	CTRP2	6.7251	9.0146	5.0812	2.9083
BT 340	CTRP2	6.8976	10.5918	4.4366	5.2778
BT 248	CTRP2	6.9929	13.3721	3.1379	10.425
BT 440	CTRP2	7.0184	8.7581	5.3876	1.3524
BT 216	CTRP2	7.1522	10.4218	4.6959	3.8528
BT 139	CTRP2	7.1892	9.2267	5.2757	1.5778
BT 498	CTRP2	7.2123	8.6866	5.5229	0.7224
BT 444	CTRP2	7.2819	8.9349	5.4536	0.8846
BT 232	CTRP2	7.334	10.0114	5.0048	2.4185
BT147	CTRP2	7.3518	9.7555	5.132	1.927
BT 224	CTRP2	7.3615	9.5062	5.2488	1.4998
BT 422	CTRP2	7.4231	9.3843	5.3352	1.1501
BT 320	CTRP2	7.4406	8.5554	5.6767	0.2092
BT 228	CTRP2	7.4499	8.74	5.6112	0.3417
BT 359	CTRP2	7.5541	20.6757	-0.0543	20.4387
BT 328	CTRP2	7.5954	9.2579	5.4727	0.6105
BT 333	CTRP2	7.7013	9.1015	5.5794	0.3041
BT 330	CTRP2	7.8156	9.1459	5.6087	0.2108
BT 504	CTRP2	7.8724	8.8821	5.7216	0.0568
BT 271	CTRP2	7.9033	9.4358	5.5371	0.3125
BT 187	CTRP2	7.9129	10.7632	5.0001	1.8368
BT 159	CTRP2	7.9332	9.2224	5.6261	0.1533
BT 482	CTRP2	7.9988	9.5612	5.5291	0.294
BT 428	CTRP2	8.0283	9.7984	5.4524	0.4388
BT 131	CTRP2	8.0567	9.5236	5.5654	0.2132
BT 245	CTRP2	8.1486	9.9128	5.4592	0.3756
BT 416	CTRP2	8.1682	15.6915	2.8557	9.6642
BT 172	CTRP2	8.217	9.5123	5.6284	0.0973
BT 231	CTRP2	8.7124	10.3951	5.5019	0.1542

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-38	CTRP2	5.8914	10.658	3.6089	10.5213

Cancer Drug Sensitivity Data Curated from 55 Cell Line(s) in Central Nervous System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
KS-1 [Human Krukenberg tumour]	GDSC2	5.115	7.896	3.1449	5.4352
D-263MG	GDSC2	5.622	12.4795	1.2694	15.0235
SF539	GDSC2; CTRP2	5.7588	9.3296	4.1581	8.4964
GB-1	GDSC2; CTRP2	5.785	9.2902	4.2005	8.2651
D283 Med	GDSC2; CTRP2	5.849	7.3972	5.1989	3.95
SF268	GDSC2; CTRP2	6.0515	9.8827	4.1311	8.0263
LN-405	GDSC2	6.1366	8.0651	3.6597	1.0493
LN-229	GDSC2; CTRP2	6.1506	10.6643	3.8223	9.1284
M059J	GDSC2	6.1536	8.0701	3.6655	1.011
SNU-489	CTRP2	6.2592	7.6964	5.3899	2.3633
SNU-738	CTRP2	6.547	8.1914	5.3553	2.0579
DK-MG	GDSC2; CTRP2	6.5853	11.3823	3.8117	8.3795
T98G	GDSC2; CTRP2	6.6301	8.0727	5.4669	1.5022
KNS-60	CTRP2	6.6563	7.9385	4.6218	0.255
A-172	GDSC2; CTRP2	6.6878	10.1971	4.4768	5.4458
Daoy	GDSC2; CTRP2	6.7143	13.0846	3.0658	11.199
ONS-76	GDSC2; CTRP2	6.8458	10.4626	4.4624	5.2529
PFSK-1	GDSC2	6.8802	8.6819	3.7356	0.3556
SK-MG-1	GDSC2	6.9127	9.0378	3.6189	0.6445
SF126	CTRP2	6.93	9.4376	5.017	2.8785
AM-38	GDSC2	6.9752	8.5633	3.8118	0.1823
U-118MG	GDSC2; CTRP2	7.0071	9.7714	4.9093	3.2018
SW1088	GDSC2; CTRP2	7.0163	9.5894	5.0017	2.8237
U-87MG ATCC	GDSC2; CTRP2	7.0356	9.6552	4.9831	3.3171
GI-1	GDSC2	7.089	8.8328	3.7598	0.2401
8-MG-BA	GDSC2; CTRP2	7.098	9.8799	4.9176	3.0469
Becker	GDSC2; CTRP2	7.1163	11.5153	4.1426	6.1428
SNU-466	CTRP2	7.1524	9.0944	5.3138	1.4787
YH-13	GDSC2; CTRP2	7.1584	12.6539	3.6158	8.2226
SNU-626	CTRP2	7.1801	8.7879	5.4635	0.9365
Hs 683	CTRP2	7.2777	11.0217	4.4934	4.4874
YKG-1	CTRP2	7.3688	11.1358	4.4998	4.336
H4	GDSC2	7.3766	19.452	-0.8732	20.0701
D-392MG	GDSC2	7.4501	10.1817	3.411	0.9686
KINGS-1	GDSC2	7.582	19.8078	-0.9011	19.7508
GaMG	GDSC2; CTRP2	7.6057	10.9149	4.7546	3.0455
SNU-201	CTRP2	7.6669	8.8273	5.6662	0.1593
KNS-81	CTRP2	7.7071	8.8649	5.668	0.1466
U-251MG	GDSC2; CTRP2	7.7878	9.5144	5.4581	0.5405
LN-18	GDSC2; CTRP2	7.7994	8.7723	5.7333	0.0555
SF295	CTRP2	7.8274	9.1099	5.6262	0.1791
NMC-G1	CTRP2	7.8278	9.641	5.4262	0.5993
CCF-STTG1	CTRP2	7.8603	12.2739	4.2817	4.5469
42-MG-BA	GDSC2; CTRP2	7.8783	17.6315	1.6991	14.358
CAS-1	GDSC2; CTRP2	7.9549	9.237	5.629	0.1444
SNU-1105	CTRP2	7.9992	13.3871	3.8465	6.9779
GOS-3	CTRP2	8.007	13.6534	3.725	6.525
SNB-75	CTRP2	8.2286	14.4374	3.4989	7.1026
GMS-10	CTRP2	8.284	13.848	3.8138	5.8133
M059K	CTRP2	8.3054	9.4376	5.684	0.0424
KNS-42	CTRP2	8.4148	9.7537	5.6158	0.0822
KALS-1	GDSC2; CTRP2	8.476	14.4387	3.6594	6.1593
DBTRG-05MG	GDSC2; CTRP2	8.8797	10.4271	5.55	0.083
TM-31	CTRP2	10.1656	17.5105	3.2726	5.6234
KG-1-C	CTRP2	11.4533	39.7089	-6.5204	27.3162

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Digestive System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
TGBC24TKB	GDSC2	6.1953	9.8954	2.8984	4.7887
ETK-1	GDSC2	7.3344	9.3637	3.6642	0.3486

Cancer Drug Sensitivity Data Curated from 23 Cell Line(s) in Endometrium Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HEC-1-B	CTRP2	4.5719	9.5021	2.9748	18.4499
MFE-280	GDSC2	5.1577	9.0255	2.6251	8.5056
HEC-151	CTRP2	5.1597	8.2277	4.1497	9.8537
RL95-2	GDSC2; CTRP2	6.1231	10.1248	4.0694	9.4063
JHUEM-7	CTRP2	6.1442	8.3194	4.989	4.2474
JHUEM-2	CTRP2	6.2683	8.6359	4.9301	4.269
HEC-59	CTRP2	6.4721	9.7125	4.5534	5.4884
ESS-1	GDSC2; CTRP2	6.5088	10.1216	4.3787	6.1538
HEC-1-A	CTRP2	6.522	8.0911	5.3866	1.9677
JHUEM-1	CTRP2	6.8397	9.0366	5.1479	2.4816
HEC-108	CTRP2	6.9981	8.8426	5.3376	1.5571
EN	GDSC2; CTRP2	7.0376	8.8528	5.3561	1.4463
EFE-184	CTRP2	7.3942	10.5879	4.7749	3.224
AN3-CA	GDSC2; CTRP2	7.4343	10.3464	4.9117	2.6525
KLE	GDSC2; CTRP2	7.4707	9.9803	5.0996	1.9191
HEC-6	CTRP2	7.5785	11.5878	4.4232	4.3583
HEC-50B	CTRP2	7.5799	10.542	4.9098	2.4942
HEC-265	CTRP2	7.7687	8.9374	5.6654	0.1359
HEC-251	CTRP2	7.8362	13.917	3.4828	7.7185
MFE-319	GDSC2; CTRP2	8.3362	10.2437	5.4122	0.3987
JHUEM-3	CTRP2	8.3499	10.2079	5.431	0.3572
MFE-296	GDSC2; CTRP2	8.5377	10.3059	5.4686	0.2366
Ishikawa (Heraklio) 02 ER-	CTRP2	7.4961	12.9292	3.7239	7.2615

Cancer Drug Sensitivity Data Curated from 29 Cell Line(s) in Kidney Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
UO-31	CTRP2	1.4581	65.6367	-27.655	47.5175
RXF 393L	GDSC2	5.1417	8.9735	2.6389	8.46
CAL-54	GDSC2; CTRP2	5.2353	10.5624	3.0801	14.0688
KTCTL-195	GDSC2	5.7937	17.7851	-1.2259	24.7202
LB996-RCC	GDSC2	5.8603	10.6045	2.3518	8.5418
SN12C	GDSC2	5.925	8.1209	3.5335	1.8375
A-704	GDSC2	6.561	8.3597	3.7284	0.5164
ACHN	GDSC2; CTRP2	6.5643	9.6336	4.6625	4.8787
NCC010	GDSC2	6.6076	9.2332	3.4085	1.6512
TK-10	GDSC2	6.6551	8.8923	3.566	0.9841
HA7-RCC	GDSC2	6.7232	9.0585	3.5311	1.0592
SW13	GDSC2	6.7751	8.7831	3.6578	0.6056
TUHR4TKB	CTRP2	6.8278	9.8534	4.7467	4.1154
Caki-1	CTRP2	6.9009	11.2378	4.1223	6.5645
BFTC-909	GDSC2; CTRP2	6.9603	9.2071	5.1457	2.3324
VMRC-RCZ	GDSC2; CTRP2	7.0606	8.9984	5.3038	1.6129
KMRC-1	CTRP2	7.0988	10.2299	4.7517	3.7035
A-498	GDSC2; CTRP2	7.1897	10.0998	4.8733	3.1012
OS-RC-2	GDSC2; CTRP2	7.1972	9.968	4.9399	3.2717
Caki-2	CTRP2	7.3134	9.972	5.0104	2.4214
RCC10RGB	GDSC2; CTRP2	7.36	9.7806	5.1254	1.9422
TUHR10TKB	CTRP2	7.365	8.4274	5.6937	0.2033
SNU-1272	CTRP2	7.4391	9.1902	5.4256	0.8507
KMRC-20	GDSC2; CTRP2	7.7898	10.0767	5.23	1.1883
KMRC-2	CTRP2	7.9247	9.3256	5.586	0.2168
786-O	GDSC2; CTRP2	8.0872	13.6236	3.7921	6.6004
VMRC-RCW	CTRP2	8.2898	9.7122	5.5857	0.1323
769-P	GDSC2; CTRP2	8.39	9.7711	5.6012	0.0991
TUHR14TKB	CTRP2	8.8491	11.0416	5.3232	0.8334

Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Large Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
SNU-C1	GDSC2; CTRP2	3.5495	7.121	2.967	18.7295
SW48	GDSC2; CTRP2	3.7492	8.2238	2.7319	19.0724
LS513	GDSC2; CTRP2	4.7965	7.0316	4.327	10.0566
SK-CO-1	GDSC2; CTRP2	5.2209	7.9677	4.3327	8.9595
SNU-175	GDSC2; CTRP2	5.2699	18.3742	-0.7773	26.7109
GP5d	GDSC2	5.5422	8.0205	3.3635	3.3035
SW1463	GDSC2	5.5496	8.9095	2.9529	5.6711
SW948	GDSC2; CTRP2	5.5711	8.4176	4.4435	7.7018
HT115	GDSC2; CTRP2	5.5751	9.4323	3.9451	9.7707
SW626	GDSC2	5.6376	9.7205	2.6248	7.4258
SW837	GDSC2	5.6749	8.4758	3.235	3.7991
DiFi	GDSC2	5.692	8.2323	3.3561	3.0943
HCC2998	GDSC2	5.7681	8.6367	3.2174	3.7372
SNU-407	GDSC2; CTRP2	5.8535	9.0234	4.393	7.3187
LS1034	GDSC2; CTRP2	6.0487	7.5042	5.318	3.045
SNU-1040	GDSC2	6.0895	8.0835	3.6304	1.2139
HT-55	GDSC2; CTRP2	6.1415	8.4672	4.913	4.5717
SW620	GDSC2; CTRP2	6.2744	13.1835	2.6647	13.6045
SW1417	GDSC2; CTRP2	6.3251	9.0849	4.7513	4.9171
NCI-H716	GDSC2; CTRP2	6.3476	9.712	4.4568	6.1101
SNU-81	GDSC2	6.3653	7.9383	3.8054	0.4023
HCT 8	CTRP2	6.3682	7.7267	5.4555	1.9159
CCK-81	GDSC2; CTRP2	6.4063	9.3491	4.6831	5.0603
HCT 15	GDSC2; CTRP2	6.4412	8.3363	5.21	2.8117
LS180	GDSC2; CTRP2	6.4567	9.9417	4.4278	6.0392
CaR-1	GDSC2	6.4689	8.161	3.7648	0.4615
COLO 320HSR	GDSC2	6.5129	9.2269	3.3651	1.9424
NCI-H747	GDSC2; CTRP2	6.5363	10.4026	4.2604	6.5995
SNU-C2B	GDSC2	6.5855	12.5069	1.9272	9.4181
COLO 320	CTRP2	6.5933	10.1901	4.4093	5.8828
COLO201	CTRP2	6.6286	8.5153	5.2554	2.3438
HCC-56	CTRP2	6.6389	8.2873	5.3713	1.8664
HCT 116	GDSC2; CTRP2	6.7341	8.2994	5.4267	1.528
NCI-H508	CTRP2	6.7451	8.4939	5.3427	1.8394
SNU-61	GDSC2; CTRP2	6.877	10.2168	4.6048	4.6206
C2BBe1	GDSC2; CTRP2	7.0165	11.3912	4.1315	6.3432
SNU-C4	CTRP2	7.0349	10.0406	4.7993	3.6022
COLO205	GDSC2; CTRP2	7.1414	9.9435	4.9157	2.9976
RCM-1 [Human ESC]	GDSC2; CTRP2	7.2783	9.5189	5.1959	1.7728
SNU-C5	GDSC2; CTRP2	7.2821	10.5596	4.7162	3.5969
DLD-1	CTRP2	7.4042	8.5262	5.6729	0.2293
SNU-503	CTRP2	7.4994	9.0051	5.5296	0.516
GP2d	CTRP2	7.5315	9.267	5.4389	0.7455
CW-2	GDSC2; CTRP2	7.5943	14.9633	2.8015	10.7558
MDST8	GDSC2; CTRP2	7.6685	9.2417	5.512	0.4698
OUMS-23	CTRP2	7.6871	12.7742	3.9305	6.1586
RKO	GDSC2; CTRP2	7.709	12.2924	4.175	5.1611
HT-29	GDSC2; CTRP2	7.736	9.019	5.6238	0.2089
LS411N	GDSC2; CTRP2	7.8464	9.044	5.6567	0.1307
SW1116	GDSC2; CTRP2	7.9487	9.7602	5.433	0.5199
LS123	GDSC2; CTRP2	8.0607	10.0146	5.3831	0.584
CL-11	GDSC2; CTRP2	8.2706	10.6633	5.2213	0.8832
LoVo	GDSC2; CTRP2	8.555	10.5597	5.3833	0.376
COLO 678	GDSC2; CTRP2	8.6076	15.1593	3.4051	6.9576
KM12	GDSC2; CTRP2	8.8678	10.4804	5.5279	0.1033
T84	GDSC2; CTRP2	8.8755	10.9322	5.3731	0.2958
SNU-C2A	CTRP2	9.0719	16.8765	2.8958	8.2578

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
MO-T	GDSC2	5.9486	7.5729	3.7697	0.7791

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Liver Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JHH-4	GDSC2; CTRP2	3.3773	9.3091	1.8747	23.2767
SNU-398	GDSC2	4.3418	7.0496	2.9747	8.4688
Huh-7	GDSC2	5.5758	9.1939	2.8349	6.3145
HLE	GDSC2	5.8851	11.9736	1.7076	12.0925
JHH-7	GDSC2	5.9857	16.7131	-0.5476	21.9905
SNU-761	CTRP2	6.0805	11.1799	2.7914	8.1687
JHH-1	GDSC2; CTRP2	6.2845	9.656	4.4346	6.3168
SK-HEP-1	GDSC2; CTRP2	6.3944	10.3508	4.1755	7.2034
SNU-878	CTRP2	6.4785	8.1854	5.3106	2.3405
Hep-G2/C3A	GDSC2	6.5099	7.8973	3.8745	0.1951
SNU-449	GDSC2; CTRP2	6.6279	10.5196	4.2725	6.3931
Hep-G2	CTRP2	6.6742	10.1038	4.5127	5.3196
HLF	CTRP2	6.7098	9.3524	4.9068	3.6402
SNU-423	GDSC2; CTRP2	6.7554	11.311	3.9776	7.4011
HuH-1	GDSC2; CTRP2	6.8196	9.913	4.7119	4.2701
Hep 3B2.1-7	GDSC2; CTRP2	6.8451	10.5587	4.4148	6.2931
SNU-182	CTRP2	6.8667	17.8149	0.8296	19.0275
HuH-6	CTRP2	7.3328	10.1099	4.9587	2.5942
JHH-5	CTRP2	7.4149	9.2055	5.407	0.9264
JHH-6	GDSC2; CTRP2	7.5684	8.483	5.7505	0.0704
SNU-475	CTRP2	7.6044	12.2976	4.1029	5.5894
PLC/PRF/5	CTRP2	7.8172	9.2217	5.5817	0.258
Li-7	CTRP2	8.494	10.2569	5.4695	0.2466
JHH-2	GDSC2; CTRP2	8.5043	10.022	5.5558	0.1289
SNU-387	GDSC2; CTRP2	8.5501	10.2777	5.4833	0.212

Cancer Drug Sensitivity Data Curated from 191 Cell Line(s) in Lung Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HCC2108	CTRP2	3.7152	9.7326	2.0239	21.8307
DV-90	CTRP2	4.2144	9.7385	2.515	18.7033
COR-L51	CTRP2	4.696	10.3492	2.6859	16.8703
NCI-H1341	CTRP2	4.7715	9.0133	3.4004	13.8312
Lu-165	GDSC2	4.8576	12.4724	0.684	19.8814
NCI-H596	GDSC2	4.8624	6.5594	3.6153	3.1252
NCI-H250	GDSC2	5.0218	10.9937	1.5499	15.0852
HCC1588	CTRP2	5.0418	8.577	3.8693	11.2796
NCI-H1048	GDSC2	5.0814	9.6343	2.2691	10.8324
NCI-H345	GDSC2	5.1769	7.828	3.22	4.846
NCI-H446	GDSC2; CTRP2	5.2063	10.2832	3.1916	13.6801
UMC-11	GDSC2	5.2123	7.0466	3.6107	2.478
NCI-H2227	GDSC2	5.2919	10.2512	2.1217	11.174
NCI-H2405	GDSC2; CTRP2	5.3037	11.0747	2.8881	16.8736
NCI-H3255	GDSC2	5.3073	8.126	3.1651	4.9035
NCI-H2818	GDSC2	5.3328	8.3918	3.0553	5.5078
NCI-H211	GDSC2; CTRP2	5.3587	8.0131	4.4431	8.1826
NCI-H1781	GDSC2	5.3869	10.3216	2.1567	10.7407
RERF-LC-KJ	GDSC2	5.3977	7.4546	3.5354	2.5857
COLO 668	GDSC2; CTRP2	5.41	10.0402	3.496	11.9873
NCI-H322M	GDSC2	5.4478	10.9762	1.8801	12.1735
NCI-H82	GDSC2	5.5077	7.3321	3.6524	1.7907
COR-L311	GDSC2	5.5201	7.5598	3.5588	2.2638
COR-L23	GDSC2	5.6107	8.5599	3.1565	4.3629
Calu-6	GDSC2; CTRP2	5.6283	9.0014	4.2063	8.5679
NCI-H3122	GDSC2	5.6532	8.7014	3.1173	4.5102
NCI-H2869	GDSC2	5.6905	7.8637	3.5195	2.2201
NCI-H2795	GDSC2	5.6946	16.6497	-0.7387	23.3654
NCI-H1975	GDSC2	5.7018	7.8799	3.5187	2.2084
HCC44	GDSC2; CTRP2	5.7404	10.0795	3.7683	10.1629
NCI-H2228	GDSC2; CTRP2	5.7444	10.6115	3.5063	11.2427
NCI-H526	GDSC2; CTRP2	5.8211	9.0434	4.355	7.5438
DMS 79	GDSC2	5.8547	8.9727	3.1158	4.1587
NCI-H650	GDSC2; CTRP2	5.8624	10.8055	3.5106	10.9864
NCI-H23	GDSC2; CTRP2	5.9138	8.5301	4.6911	5.9456
NCI-H720	GDSC2	5.9266	12.723	1.372	13.7684
NCI-H2135	GDSC2	5.9688	7.901	3.6473	1.2616
LC-1/sq	GDSC2	5.9821	9.429	2.9835	4.6807
A-427	GDSC2	5.9869	15.6122	-0.0029	19.9193
Lu-99	CTRP2	6.1045	7.2025	5.5147	2.1132
NCI-H1105	CTRP2	6.1065	10.6952	3.7705	9.4285
NCI-H1993	GDSC2	6.1171	7.9676	3.6896	0.9476
LK2	CTRP2	6.1636	9.9894	4.1703	7.6483
HOP-62	GDSC2; CTRP2	6.21	9.6017	4.4018	6.5909
NCI-H1666	GDSC2; CTRP2	6.2107	10.5943	3.9065	8.6639
NCI-H1915	GDSC2; CTRP2	6.235	10.0081	4.219	7.311
NCI-H2731	GDSC2	6.2422	8.641	3.475	1.7409
NCI-H1184	CTRP2	6.2448	9.7139	4.3738	6.6439
Lu-139	GDSC2	6.2488	8.0551	3.7136	0.756
Lu-65	GDSC2; CTRP2	6.2569	10.5235	3.9793	8.2737
NCI-H2369	GDSC2	6.2806	7.7577	3.838	0.3565
Lu-135	GDSC2	6.2876	8.0874	3.7178	0.7138
NCI-H1944	GDSC2; CTRP2	6.2972	9.2597	4.6422	5.4236
SBC-3	GDSC2	6.3035	8.0374	3.7435	0.6182
EBC-1	GDSC2; CTRP2	6.308	9.2338	4.6637	5.3143
NCI-H2171	CTRP2	6.3189	7.9215	5.3236	2.5393
RERF-LC-A1	CTRP2	6.3218	9.4762	4.5539	5.7496
NCI-H1694	GDSC2; CTRP2	6.3357	8.0629	5.2665	2.749
CPC-N	GDSC2	6.3435	8.85	3.4382	1.7966
NCI-H2444	CTRP2	6.3479	7.4368	4.6834	0.2461
MOR/CPR	CTRP2	6.3557	7.5239	5.5453	1.5677
NCI-H2461	GDSC2	6.418	8.5627	3.59	1.0819
NCI-H524	GDSC2; CTRP2	6.4299	9.0404	4.8543	4.3059
NCI-H2722	GDSC2	6.4393	8.0768	3.7839	0.4242
NCI-H1155	GDSC2; CTRP2	6.5041	9.519	4.6738	4.9324
NCI-H292	CTRP2	6.5123	9.3881	4.7447	4.624
NCI-H1355	GDSC2; CTRP2	6.5255	10.3658	4.2703	6.5769
NCI-H2110	CTRP2	6.545	9.6057	4.6617	4.9142
NCI-H1734	CTRP2	6.5844	8.3371	5.3109	2.1837
NCI-H647	CTRP2	6.61	11.585	3.7302	8.6735
EKVX	GDSC2; CTRP2	6.6182	13.017	3.024	11.5389
NCI-H1963	GDSC2	6.6471	8.6608	3.6511	0.7002
NCI-H2170	GDSC2; CTRP2	6.6473	12.0023	3.5517	9.3434
SK-LU-1	GDSC2; CTRP2	6.6698	12.342	3.4004	9.9233
NCI-H2804	GDSC2	6.6824	9.3212	3.4082	1.5795
NCI-H2803	GDSC2	6.6829	8.3052	3.7952	0.2966
NCI-H1703	CTRP2	6.6839	8.6921	5.2081	2.4555
NCI-H661	GDSC2; CTRP2	6.7222	9.7628	4.7154	4.4061
NCI-H1339	CTRP2	6.7296	9.037	5.0734	2.9331
NCI-H2373	GDSC2	6.7326	8.6445	3.6919	0.5306
NCI-H2081	CTRP2	6.742	8.391	5.389	1.6634
NCI-H1876	GDSC2	6.7459	8.2537	3.8363	0.1984
NCI-H146	CTRP2	6.747	15.174	2.0511	15.0563
ABC-1	GDSC2	6.7816	10.8107	2.8256	4.2537
Lu-99A	GDSC2	6.7911	8.847	3.6405	0.6479
COR-L95	CTRP2	6.8174	8.5232	5.3747	1.6262
ChaGo-K-1	CTRP2	6.8196	13.0172	3.1811	10.5503
NCI-H522	GDSC2; CTRP2	6.821	10.2136	4.5662	4.8649
IST-SL2	GDSC2	6.8284	9	3.5985	0.7557
NCI-H841	GDSC2; CTRP2	6.829	9.0876	5.1166	2.6201
NCI-H1092	GDSC2; CTRP2	6.8566	10.6961	4.3558	5.6742
NCI-H209	GDSC2	6.8575	11.9557	2.354	6.6262
NCI-H1693	GDSC2; CTRP2	6.8854	8.9364	5.2248	2.1197
NCI-H2141	GDSC2; CTRP2	6.9065	11.1743	4.1576	6.4102
SW1271	GDSC2; CTRP2	6.9225	9.1916	5.1286	2.4477
Ms-1	GDSC2	6.9348	8.6138	3.7799	0.247
VMRC-LCD	GDSC2; CTRP2	6.9566	8.3394	5.5383	0.884
SK-MES-1	GDSC2; CTRP2	6.9825	10.5551	4.5149	4.8276
NCI-H513	GDSC2	6.986	9.628	3.4246	1.249
LC-1/sq-SF	CTRP2	7.0095	9.5457	5.0179	2.7687
RERF-LC-MS	CTRP2	7.0325	11.4834	4.098	6.4553
NCI-H838	CTRP2	7.0459	8.6638	5.4451	1.1207
NCI-H1568	GDSC2; CTRP2	7.0577	13.7546	2.9978	10.8728
PC-14	GDSC2; CTRP2	7.0644	9.7165	4.9729	2.8736
LUDLU-1	CTRP2	7.0875	12.0236	3.8732	7.2876
NCI-H727	GDSC2; CTRP2	7.0982	9.9867	4.8672	3.7495
HCC95	CTRP2	7.1113	9.7643	4.9806	2.7827
HCC1195	CTRP2	7.1164	16.4407	1.7104	15.6187
RERF-LC-Sq1	GDSC2	7.1286	9.856	3.3985	1.2346
NCI-H1573	CTRP2	7.1425	9.5269	5.111	2.2417
NCI-H69	CTRP2	7.1685	9.7597	5.0191	2.5617
EMC-BAC-2	GDSC2	7.1703	9.1492	3.6788	0.3745
NCI-H1395	CTRP2	7.1756	11.5335	4.1759	5.9171
A-549	GDSC2; CTRP2	7.2124	9.2492	5.2789	1.5421
RERF-LC-Ad1	CTRP2	7.2331	8.0988	5.7618	0.1254
NCI-H2595	GDSC2	7.2342	9.5409	3.562	0.6377
DMS 53	GDSC2; CTRP2	7.2435	9.5019	5.1832	1.8566
NCI-H322	CTRP2	7.2642	8.7528	5.521	0.6902
DMS 114	GDSC2; CTRP2	7.2741	9.1553	5.3548	1.2167
COR-L105	GDSC2; CTRP2	7.2853	10.8903	4.5612	4.2062
HCC366	GDSC2; CTRP2	7.2959	10.4348	4.784	3.3132
SHP-77	GDSC2; CTRP2	7.3116	11.3348	4.3662	4.9489
NCI-H226	GDSC2; CTRP2	7.3118	8.988	5.4464	0.8836
NCI-H1792	GDSC2; CTRP2	7.3292	11.475	4.3109	5.1459
LCLC-103H	GDSC2; CTRP2	7.3445	9.2156	5.3663	1.1153
NCI-H1299	GDSC2; CTRP2	7.3517	9.9085	5.0625	2.1824
LK-2	GDSC2	7.37	18.1008	-0.2224	17.7263
SBC-5	GDSC2; CTRP2	7.3726	8.3055	5.7409	0.1213
COLO 699	CTRP2	7.3799	13.5833	3.3217	9.0526
NCI-H2023	GDSC2; CTRP2	7.3839	9.9985	5.0407	2.2277
RERF-LC-Ad2	CTRP2	7.4782	10.1273	5.0378	2.135
NCI-H1581	GDSC2; CTRP2	7.4841	9.3408	5.3851	0.9413
NCI-H2810	GDSC2	7.522	9.7972	3.5809	0.4622
Calu-3	GDSC2; CTRP2	7.5238	13.5146	3.4589	8.2804
Calu-1	CTRP2	7.5583	10.3143	5.0001	2.1867
KNS-62	GDSC2; CTRP2	7.5734	9.2408	5.4694	0.6329
NCI-H1755	GDSC2; CTRP2	7.5805	9.8528	5.2167	1.4061
BEN	CTRP2	7.5896	8.5871	5.7222	0.0989
NCI-H2106	CTRP2	7.5968	10.3071	5.0255	2.0548
IA-LM	GDSC2; CTRP2	7.6115	9.0578	5.5584	0.3879
NCI-H2087	GDSC2; CTRP2	7.6144	14.1759	3.2012	9.163
NCI-H2126	CTRP2	7.6299	8.8679	5.6372	0.2186
Sq-1	CTRP2	7.6409	8.9938	5.595	0.2959
NCI-H196	GDSC2; CTRP2	7.6433	9.7926	5.2753	1.1613
NCI-H1373	CTRP2	7.7304	12.2728	4.1983	5.0409
NCI-H2591	GDSC2	7.7696	9.8739	3.6451	0.2591
NCI-H2291	CTRP2	7.8029	14.1977	3.324	8.3928
NCI-H2196	CTRP2	7.8431	9.2446	5.5836	0.246
HCC2935	CTRP2	7.8526	9.9245	5.3239	0.8614
DMS 273	GDSC2; CTRP2	7.8544	10.2973	5.1696	1.3278
CAL-12T	CTRP2	7.9145	10.1129	5.2766	0.9562
NCI-H889	CTRP2	7.9723	19.4032	0.8957	16.8825
NCI-H1563	GDSC2; CTRP2	7.9814	9.4559	5.5608	0.2426
HOP-92	GDSC2; CTRP2	8.0017	17.4715	1.8686	16.6065
HCC1438	CTRP2	8.0231	10.1508	5.3124	0.7861
NCI-H1838	CTRP2	8.0291	9.9517	5.3937	0.5741
HCC4006	CTRP2	8.0699	9.5904	5.5464	0.2405
LXF 289	GDSC2; CTRP2	8.0763	12.4006	4.3577	3.992
SW1573	GDSC2; CTRP2	8.0836	12.9719	4.0968	4.9789
EPLC-272H	GDSC2; CTRP2	8.0935	10.1431	5.3474	0.6551
HCC78	GDSC2; CTRP2	8.0972	12.6537	4.2536	5.0323
NCI-H460	CTRP2	8.1032	9.2689	5.6712	0.0722
NCI-H2122	GDSC2; CTRP2	8.1329	9.774	5.5042	0.2948
NCI-H1793	GDSC2; CTRP2	8.1348	9.6869	5.5367	0.2379
LOU-NH91	GDSC2; CTRP2	8.1681	9.5541	5.5964	0.1426
NCI-H2342	CTRP2	8.1816	14.6305	3.3753	7.6459
NCI-H2286	CTRP2	8.2101	9.3749	5.6725	0.0589
NCI-H2009	CTRP2	8.2192	13.3306	4.0149	5.1233
T3M-10	CTRP2	8.2218	12.5994	4.3547	3.8351
NCI-H2029	GDSC2; CTRP2	8.3271	9.92	5.5265	0.2029
NCI-H441	GDSC2; CTRP2	8.3539	10.4567	5.3392	0.5466
NCI-H1623	GDSC2; CTRP2	8.384	15.7312	2.9848	8.8602
HARA [Human squamous cell lung carcinoma]	GDSC2; CTRP2	8.4021	9.8047	5.594	0.1045
LCLC-97TM1	GDSC2; CTRP2	8.4468	14.7845	3.4777	6.8915
NCI-H2172	CTRP2	8.4554	9.8332	5.6031	0.0884
NCI-H1869	GDSC2; CTRP2	8.4763	15.1708	3.314	7.478
NCI-H2085	GDSC2; CTRP2	8.4905	10.3883	5.4206	0.3293
NCI-H2030	CTRP2	8.4983	10.3126	5.4511	0.2952
NCI-H1435	GDSC2; CTRP2	8.5273	9.8009	5.6386	0.0529
NCI-H810	GDSC2; CTRP2	8.6609	15.1965	3.4219	6.8248
HCC1833	CTRP2	8.6967	16.8985	2.637	9.7216
NCI-H1650	GDSC2; CTRP2	8.7722	10.5214	5.4797	0.1697
NCI-H358	GDSC2; CTRP2	8.8845	10.8784	5.3958	0.2588
HCC827	GDSC2; CTRP2	9.1105	17.5286	2.6125	9.8525
HCC15	GDSC2; CTRP2	9.2169	17.0939	2.8869	8.1033
DMS 454	CTRP2	9.298	11.3975	5.3664	0.2079
HCC2279	CTRP2	10.0885	22.1551	1.059	13.1933
NCI-H520	GDSC2; CTRP2	10.1583	19.6935	2.2678	9.1188
HCC1171	CTRP2	10.915	21.1796	2.0479	8.9603
NCI-H1651	GDSC2; CTRP2	12.912	32.4335	-1.9591	17.6251
Hs 888.Lu	CTRP2	7.0069	10.4841	4.5665	4.5817

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
CBTCi002-A	GDSC2	6.8859	9.1613	3.5615	0.839

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Ovary Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
2004	CTRP2	6.9243	15.4448	2.0559	14.7165
SNU-8	CTRP2	3.9795	11.0888	1.6466	22.5082
COV434	CTRP2	4.3929	10.0702	2.5313	18.1998
HEY A8	CTRP2	4.5158	8.7847	3.2579	15.028
TOV-21G	GDSC2	4.7123	8.4968	2.5503	10.0901
OVCAR-3	GDSC2	4.9069	7.1403	3.3655	4.5517
ES-2	GDSC2	5.2261	7.8036	3.2647	4.4753
SNU-840	CTRP2	5.8879	12.3508	2.7599	13.9858
OVSAHO	CTRP2	5.9417	12.3251	2.818	15.6353
DOV13	GDSC2; CTRP2	6.3383	8.7663	4.92	4.1887
OVCAR-8	GDSC2; CTRP2	6.5601	9.773	4.5905	5.1851
IGROV-1	GDSC2; CTRP2	6.5631	8.8132	5.0649	3.2176
TYK-nu	GDSC2; CTRP2	6.6311	8.8876	5.0771	3.0635
JHOS-2	CTRP2	6.6328	8.7509	5.1446	2.7863
OVCAR-5	GDSC2; CTRP2	6.661	9.7999	4.6525	4.7627
EFO-21	GDSC2; CTRP2	6.7046	11.5363	3.8273	8.1083
OC 314	CTRP2	6.7242	8.3192	5.4113	1.5995
OVK18	GDSC2; CTRP2	6.7316	8.9209	5.1307	2.6993
A2780	GDSC2; CTRP2	6.732	8.4314	5.3637	1.7744
OVCAR-4	GDSC2; CTRP2	6.776	11.7979	3.7522	8.2963
TOV-112D	GDSC2; CTRP2	6.8447	10.2108	4.5846	4.7525
MCAS	CTRP2	6.8896	9.811	4.8105	3.7643
OVISE	GDSC2; CTRP2	6.9079	8.8164	5.2949	1.8218
SNU-119	CTRP2	6.9307	11.8508	3.8427	7.666
ES2	CTRP2	6.9513	9.6521	4.9289	3.2002
OAW42	GDSC2; CTRP2	6.9816	9.244	5.1419	2.3202
OVTOKO	GDSC2; CTRP2	7.0589	11.8895	3.9182	8.2425
JHOC-5	CTRP2	7.1479	8.6298	5.5142	0.7995
OV56	GDSC2; CTRP2	7.229	8.4566	5.6245	0.4219
OV7	CTRP2	7.3211	17.5167	1.3344	16.5558
COV362	CTRP2	7.3416	10.4775	4.7931	3.2195
EFO-27	GDSC2; CTRP2	7.4938	10.2809	4.9775	2.3395
ONCO-DG-1	CTRP2	7.6177	11.7793	4.3583	4.8983
JHOM-1	CTRP2	7.7399	9.0389	5.6181	0.2176
Kuramochi	GDSC2; CTRP2	7.8064	10.9953	4.8375	2.5142
COV644	CTRP2	7.8327	9.8189	5.3574	0.78
FU-OV-1	CTRP2	7.9775	9.8996	5.3913	0.6067
Caov-3	CTRP2	8.2645	9.6663	5.5924	0.129
OV-90	GDSC2; CTRP2	8.2942	9.7194	5.5848	0.1326
OAW28	GDSC2; CTRP2	8.4355	10.907	5.1995	0.8449
RMG-I	CTRP2	8.6298	10.6024	5.3973	0.3267
SK-OV-3	GDSC2; CTRP2	8.6904	14.624	3.7081	5.7081

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
U-CH1	CTRP2	7.0745	8.4779	5.541	0.7735

Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
H-STS	CTRP2	7.2739	8.2681	5.716	0.1929
SYO-1	CTRP2	7.3777	11.737	4.218	5.4495
P-STS	CTRP2	8.0306	9.6806	5.4977	0.3432

Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Soft Tissue Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Aska-SS	CTRP2	7.8083	9.1672	5.5981	0.2313
Yamato-SS	CTRP2	8.0433	9.2749	5.648	0.1041
Rh41	GDSC2; CTRP2	3.9453	6.6148	3.5758	15.3082
EW-8	GDSC2	5.3543	7.5122	3.483	2.954
Rh30	GDSC2	5.6268	7.8837	3.475	2.5502
TE 617.T	CTRP2	5.6344	8.1306	4.6426	6.7342
G-402	GDSC2; CTRP2	5.9392	8.7272	4.6144	6.2167
A-204	GDSC2; CTRP2	5.9687	10.1259	3.9402	8.987
SK-LMS-1	GDSC2; CTRP2	6.064	10.323	3.9214	8.8805
VA-ES-BJ	GDSC2	6.1071	7.9649	3.6861	0.9698
SW684	GDSC2	6.1948	7.8925	3.7529	0.658
HT-1080	GDSC2; CTRP2	6.3418	9.4304	4.5924	5.5526
SW872	GDSC2	6.5898	8.3189	3.7547	0.4305
G-401	GDSC2; CTRP2	6.662	11.3198	3.9021	7.872
TE 441.T	CTRP2	6.819	9.4108	4.9548	3.283
BT-12	CTRP2	6.9076	8.0027	5.6567	0.5409
KYM-1	GDSC2; CTRP2	7.0618	10.4669	4.6129	4.3134
MES-SA	GDSC2	7.1541	17.3453	-0.0071	17.3293
GCT	GDSC2; CTRP2	7.1606	14.1798	2.8653	11.2211
Tm87-16	CTRP2	7.3573	16.8359	1.6999	15.2331
BT-16	CTRP2	7.5555	9.0922	5.5204	0.5083
RD	GDSC2; CTRP2	7.701	12.6314	4.0082	5.8312
TTC-709	CTRP2	8.0218	18.3072	1.4728	14.9031
RKN	GDSC2; CTRP2	8.0456	9.2599	5.654	0.0972
Rh18	CTRP2	8.1554	10.477	5.2427	0.8952
SW982	GDSC2; CTRP2	8.3016	9.4752	5.6703	0.0516
SK-UT-1	GDSC2; CTRP2	8.6872	15.5985	3.2495	7.4427
Hs 729.T	CTRP2	8.9748	15.9774	3.256	7.0487

Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NCI-H28	GDSC2; CTRP2	6.3877	9.3118	4.6872	5.0755
IST-Mes1	GDSC2; CTRP2	6.9088	9.7139	4.8704	3.4946
NCI-H2052	GDSC2; CTRP2	6.9492	12.2076	3.6805	8.3
ACC-MESO-1	CTRP2	7.159	9.9922	4.9041	3.0202
MPP 89	GDSC2; CTRP2	7.2553	9.3505	5.2581	1.5724
NCI-H2452	CTRP2	8.1574	14.96	3.2009	8.355
MSTO-211H	GDSC2; CTRP2	8.1782	9.9085	5.4728	0.338
JL-1	CTRP2	8.7735	13.9673	4.06	4.3063

Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
22Rv1	GDSC2; CTRP2	5.9358	10.178	3.8864	9.2766
VCaP	GDSC2; CTRP2	6.4201	9.5609	4.5886	5.431
PC-3	GDSC2	6.5624	9.3971	3.3188	2.0991
DU145	GDSC2; CTRP2	7.6713	12.449	4.0754	5.6061
LNCaP clone FGC	GDSC2; CTRP2	7.7565	13.1582	3.7934	6.6049
PaCa-3	CTRP2	8.1429	9.2462	5.6925	0.0508

Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
YD-15	CTRP2	3.2718	8.2522	2.2227	22.2987
A-253	GDSC2; CTRP2	8.4974	9.9533	5.577	0.1076

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HuTu 80	GDSC2	5.0821	7.4782	3.3236	4.4221

Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Stomach Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
Fu97	CTRP2	0.156	291.3783	-141.5588	49.6951
SNU-16	CTRP2	3.0107	4.8357	2.9688	20.3522
SNU-620	CTRP2	3.846	7.3412	3.1987	17.0169
GSS	CTRP2	4.4658	6.6543	4.1236	11.7542
23132/87	GDSC2; CTRP2	4.9659	7.7033	4.2052	10.1
NUGC-4	GDSC2; CTRP2	5.3234	10.8831	3.0007	14.1974
RF-48	GDSC2	5.3876	8.5265	3.0277	5.5585
SNU-1	GDSC2; CTRP2	5.5291	7.3627	4.9185	5.8308
GCIY	GDSC2	5.73	9.4738	2.8037	6.1851
SNU-5	GDSC2; CTRP2	5.8242	9.0644	4.3472	7.5705
SNU-216	CTRP2	5.9765	13.7228	2.1485	16.1709
IM95	GDSC2; CTRP2	6.0488	9.8409	4.1498	7.953
OCUM-1	GDSC2	6.3797	8.9871	3.399	1.9357
RERF-GC-1B	GDSC2	6.463	11.4152	2.3612	7.2906
Hs 746.T	GDSC2; CTRP2	6.6356	9.7342	4.666	4.7477
HGC-27	GDSC2; CTRP2	6.6382	11.4055	3.8412	8.1653
NCI-N87	GDSC2; CTRP2	6.6813	9.6268	4.7523	4.3186
HuG1-N	CTRP2	6.699	12.7371	3.2267	10.578
KATO III	GDSC2; CTRP2	6.8769	9.7632	4.8247	3.7253
SH-10-TC	CTRP2	6.9555	8.7256	5.3655	1.501
SNU-668	CTRP2	6.9891	8.1617	5.6309	0.5591
SK-GT-2	GDSC2	6.9975	9.2954	3.5573	0.7826
NUGC-3	GDSC2; CTRP2	7.0049	10.0202	4.7888	3.6862
ECC12	CTRP2	7.1498	8.3618	5.6261	0.4647
MKN28	GDSC2	7.1513	13.5834	1.7831	9.1013
ECC10	GDSC2; CTRP2	7.1657	8.7469	5.4735	0.916
GSU	CTRP2	7.4681	8.1372	5.8319	0.0188
SNU-601	CTRP2	7.5462	9.3515	5.4114	0.816
MKN45	GDSC2; CTRP2	7.632	8.7693	5.6737	0.1569
MKN1	GDSC2; CTRP2	7.7941	8.9301	5.6773	0.1149
MKN7	CTRP2	7.8802	9.9557	5.3243	0.8423
AGS	GDSC2; CTRP2	8.3852	9.7341	5.6121	0.0893
MKN74	CTRP2	8.5561	10.9587	5.2328	0.6981
LMSU	CTRP2	8.648	13.4677	4.2125	3.8871
SNU-719	CTRP2	8.8217	17.9451	2.2194	11.0633
KE-39	CTRP2	9.4828	15.7878	3.6522	5.0102
SNG-M	GDSC2; CTRP2	7.7507	11.6449	4.5062	3.8179
SNU-1077	CTRP2	8.293	13.5374	3.9649	6.0164
SNU-685	CTRP2	9.4303	15.8193	3.6072	5.2274

Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Thyroid Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
ASH-3	GDSC2	4.9088	8.5485	2.6756	8.8088
HTC-C3	GDSC2	5.4448	8.734	2.967	5.8018
K5	GDSC2	5.8212	8.1942	3.4464	2.4138
8505C	GDSC2; CTRP2	6.059	9.7728	4.1924	7.7549
IHH-4	GDSC2	6.084	7.3737	3.9006	0.2857
8305C	GDSC2; CTRP2	6.8472	11.3104	4.0468	6.9631
B-CPAP	GDSC2; CTRP2	7.0663	12.4041	3.6708	8.1477
FTC-238	CTRP2	7.1052	11.2958	4.2417	5.7557
WRO	GDSC2	7.3731	18.7596	-0.5392	18.9019
TT2609-C02	GDSC2; CTRP2	7.455	12.124	4.0847	5.8736
BHT-101	GDSC2; CTRP2	7.4841	11.7108	4.3026	4.962
CGTH-W-1	CTRP2	7.5036	9.0668	5.5069	0.5734
CAL-62	GDSC2; CTRP2	7.5341	9.3311	5.4139	0.8169
FTC-133	GDSC2; CTRP2	7.5465	11.5651	4.4131	4.4403
SW579	CTRP2	7.6515	9.1862	5.5261	0.4443
TT	CTRP2	8.2979	16.3585	2.6232	10.3494
ML-1 [Human leukemia]	CTRP2	8.3675	10.2777	5.4123	0.387

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Upper Aerodigestive Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
HSC-3	GDSC2; CTRP2	3.5831	7.8635	2.7102	22.6097
YD-10B	CTRP2	3.593	7.8167	2.7398	19.4678
SAS	GDSC2	4.7862	7.9437	2.8819	7.8436
PE/CA-PJ15	CTRP2	5.0695	9.5596	3.4204	13.0536
SNU-899	CTRP2	5.1983	9.3254	3.6547	11.8
BICR 10	GDSC2	5.2053	15.8666	-0.7318	24.5741
PE/CA-PJ34 (clone C12)	CTRP2	5.3374	9.9153	3.4922	12.1609
UPCI-SCC-090	GDSC2	5.4802	17.1525	-1.1554	25.2615
DOK	GDSC2	5.8371	10.3695	2.4486	8.0323
Ca9-22	GDSC2	6.0532	8.2491	3.5445	1.6335
NCI-H3118	GDSC2	6.2841	9.6364	3.0669	3.7296
JHU-022	GDSC2	6.3082	9.7434	3.0329	3.8739
BICR 22	GDSC2; CTRP2	6.3204	11.5457	3.5203	10.0634
BB49-HNC	GDSC2	6.4513	14.9009	0.6849	15.8982
HSC-4	GDSC2; CTRP2	6.5087	10.932	3.9759	7.8324
BICR 18	CTRP2	6.5475	9.4289	4.751	4.5394
CAL-27	GDSC2; CTRP2	6.5856	10.0976	4.4493	5.7294
CAL-33	GDSC2; CTRP2	6.6214	9.0117	5.0098	3.3535
HO-1-N-1	GDSC2	6.6673	8.2764	3.7996	0.2929
SCC-15	GDSC2	6.7741	8.7653	3.664	0.5881
PE/CA-PJ49	CTRP2	6.7812	8.5428	5.3428	1.7931
BICR 6	CTRP2	6.8528	9.6124	4.8809	3.533
LB771-HNC	GDSC2	6.9356	11.6101	2.5567	5.4238
PCI-04B	GDSC2	6.9435	8.8767	3.69	0.4376
BICR 78	GDSC2	6.951	15.615	0.6878	14.8053
SKN-3	GDSC2	6.9665	8.6032	3.795	0.2116
BHY	CTRP2	6.9855	9.3008	5.1178	2.4089
YD-8	CTRP2	7.1972	14.5301	2.7198	11.7268
HSC-2	GDSC2; CTRP2	7.2425	8.6954	5.5341	0.6665
Detroit 562	GDSC2; CTRP2	7.246	13.1047	3.4587	10.0181
SNU-1214	CTRP2	7.2547	14.0311	3.0093	10.4968
SAT [Human HNSCC]	GDSC2	7.2704	11.6063	2.7442	3.9813
SNU-1076	CTRP2	7.4334	15.399	2.4682	12.2941
SCC-4	GDSC2; CTRP2	7.4864	9.5464	5.2989	1.2153
BICR 56	CTRP2	7.6139	9.0465	5.5637	0.3746
BICR 31	CTRP2	7.6212	10.5913	4.9118	2.4416
PE/CA-PJ41 (clone D2)	CTRP2	7.6723	12.0663	4.2581	4.8832
FaDu	GDSC2; CTRP2	7.8329	12.6231	4.0995	5.2922
SNU-1066	CTRP2	7.9024	13.7424	3.6121	8.1781
BICR 16	CTRP2	8.086	9.5052	5.5832	0.1786
SNU-1041	CTRP2	8.1213	15.9818	2.6821	10.3923
OSC-20	GDSC2	8.1562	22.9222	-2.0089	22.0735
SCC-9	GDSC2; CTRP2	9.5106	16.8376	3.19	6.6401
SNU-46	CTRP2	9.9069	21.907	1.0554	13.452

Cancer Drug Sensitivity Data Curated from 25 Cell Line(s) in Urinary Tract Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
JMSU-1	CTRP2	2.5298	7.044	1.8958	25.6384
5637	GDSC2; CTRP2	4.3725	9.5949	2.7372	17.447
SW780	GDSC2	4.8261	7.1393	3.3081	5.0929
647V	GDSC2; CTRP2	6.0731	9.8795	4.1507	7.9025
SCaBER	CTRP2	6.255	13.3023	2.5894	13.9363
BC-3C	CTRP2	6.6825	10.5237	4.3118	6.1387
KU-19-19	GDSC2; CTRP2	6.6847	8.6723	5.2181	2.7893
VM-CUB-1	CTRP2	6.7567	11.5437	3.8635	7.8703
SW1710	GDSC2; CTRP2	6.889	9.8565	4.7881	3.8561
253J	CTRP2	6.9583	8.9793	5.2506	1.9304
U-BLC1	CTRP2	7.0336	10.4687	4.5925	4.4369
UM-UC-3	CTRP2	7.18	8.9599	5.3889	1.1875
T24	CTRP2	7.2895	12.5067	3.783	7.3379
253J-BV	CTRP2	7.4108	9.2306	5.3943	0.9696
RT-112	GDSC2; CTRP2	7.6225	9.0084	5.5819	0.3309
BFTC-905	GDSC2; CTRP2	7.7761	9.131	5.5986	0.2406
639V	GDSC2; CTRP2	7.7792	8.8623	5.6955	0.0959
TCCSUP	GDSC2; CTRP2	7.816	12.4614	4.165	5.0582
CAL-29	GDSC2; CTRP2	8.0229	9.5185	5.5542	0.2413
HT-1376	CTRP2	8.1699	15.0459	3.1681	8.4637
J82	GDSC2; CTRP2	8.6346	16.8352	2.6252	9.853
RT-4	GDSC2; CTRP2	8.6893	10.7189	5.3781	0.3416
HT-1197	GDSC2; CTRP2	8.8098	15.5272	3.3619	6.8612
UM-UC-1	CTRP2	8.858	10.6937	5.451	0.1886
KMBC-2	CTRP2	9.0423	10.8438	5.4656	0.1392

Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Urogenital System Tissue

Cell Line	Original Dataset	IC50	IC90	EC50	AUC
NEC8	GDSC2	4.7368	6.5612	3.5264	3.9509
C-4-I	GDSC2	5.0375	7.6968	3.1872	5.3496
SiHa	GDSC2	5.1176	11.1458	1.5483	14.84
DSH1	GDSC2	5.1287	9.1919	2.5222	9.198
PWR-1E	GDSC2	5.1852	7.3499	3.4527	3.4412
C-33 A	GDSC2	5.1898	7.7231	3.2789	4.4652
CAL-39	GDSC2	5.3168	8.2426	3.1159	5.1784
BPH-1	GDSC2	5.5542	8.1847	3.2954	3.6686
TC-YIK	GDSC2	5.8103	8.8525	3.1441	4.0763
HEC-1	GDSC2	5.8607	7.673	3.6887	1.1914
SiSo	GDSC2	5.8853	12.299	1.5493	12.939
SKG-IIIa	GDSC2	5.8944	7.3794	3.8213	0.6317
HEY	GDSC2	5.9127	8.967	3.153	3.8527
MS751	GDSC2	6.1395	13.8229	0.9878	15.1888
SW756	GDSC2	6.3057	14.235	0.9056	15.2016
PEO1	GDSC2	6.3094	8.642	3.5074	1.5239
Ca Ski	GDSC2	6.3673	8.6303	3.5397	1.3292
OVCA420	GDSC2	6.3865	8.1557	3.7334	0.5993
LB831-BLC	GDSC2	6.4133	8.6457	3.5549	1.2247
SKN	GDSC2	6.4481	8.4662	3.641	0.8682
PA-1	GDSC2	6.4795	8.4203	3.6721	0.7389
HeLa	GDSC2; CTRP2	6.4881	7.9645	5.4242	1.8647
DoTc2 4510	GDSC2	6.6581	8.5033	3.7142	0.5063
ME-180	GDSC2	6.7114	10.9962	2.703	5.0042
HT-3	GDSC2	6.7551	8.4217	3.781	0.3017
OVMIU	GDSC2	7.3822	9.8973	3.4897	0.7664

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dacarbazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[19]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[20]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Roflumilast.	Asthma [CA23]	[21]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[22]
ABT-492	DMJFD2I	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[22]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[22]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Dacarbazine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[23]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Cannabidiol.	Epileptic encephalopathy [8A62]	[21]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[24]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Dacarbazine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[25]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Dacarbazine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[26]
Denosumab	DMNI0KO	Moderate	Additive myelosuppressive effects by the combination of Dacarbazine and Denosumab.	Low bone mass disorder [FB83]	[27]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[28]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Idelalisib.	Mature B-cell leukaemia [2A82]	[29]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Dacarbazine and Thalidomide.	Multiple myeloma [2A83]	[30]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Tecfidera.	Multiple sclerosis [8A40]	[31]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Siponimod.	Multiple sclerosis [8A40]	[19]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Fingolimod.	Multiple sclerosis [8A40]	[32]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Ocrelizumab.	Multiple sclerosis [8A40]	[33]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Ozanimod.	Multiple sclerosis [8A40]	[21]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[34]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Dacarbazine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[22]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Canakinumab.	Rheumatoid arthritis [FA20]	[35]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Rilonacept.	Rheumatoid arthritis [FA20]	[35]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Dacarbazine and Golimumab.	Rheumatoid arthritis [FA20]	[36]
Leflunomide	DMR8ONJ	Major	Additive myelosuppressive effects by the combination of Dacarbazine and Leflunomide.	Rheumatoid arthritis [FA20]	[37]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Dacarbazine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[38]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Dacarbazine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[21]
Azathioprine	DMMZSXQ	Moderate	Additive immunosuppressive effects by the combination of Dacarbazine and Azathioprine.	Transplant rejection [NE84]	[19]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Dacarbazine and Ganciclovir.	Virus infection [1A24-1D9Z]	[19]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Dacarbazine and Valganciclovir.	Virus infection [1A24-1D9Z]	[19]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Dacarbazine 200mg/vial injectable	200mg/vial	Injectable	Injection

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Dacarbazine FDA Label
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075259.
• [3] BDDCS applied to over 900 drugs
• [4] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
• [7] Role of cytochrome P450 isoenzymes in metabolism of O(6)-benzylguanine: implications for dacarbazine activation. Clin Cancer Res. 2001 Dec;7(12):4239-44.
• [8] Metabolic activation of dacarbazine by human cytochromes P450: the role of CYP1A1, CYP1A2, and CYP2E1. Clin Cancer Res. 1999 Aug;5(8):2192-7.
• [9] Study on mesenchymal stem cells mediated enzyme-prodrug gene CYP1A2 targeting anti-tumor effect. Zhonghua Xue Ye Xue Za Zhi. 2009 Oct;30(10):667-71.
• [10] Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 2004 Dec;14(6):543-6. doi: 10.1097/00008390-200412000-00017.
• [11] Clusterin regulates drug-resistance in melanoma cells. J Invest Dermatol. 2005 Jun;124(6):1300-7. doi: 10.1111/j.0022-202X.2005.23720.x.
• [12] Impairment of APE1 function enhances cellular sensitivity to clinically relevant alkylators and antimetabolites. Mol Cancer Res. 2009 Jun;7(6):897-906. doi: 10.1158/1541-7786.MCR-08-0519. Epub 2009 May 26.
• [13] Functional erythropoietin autocrine loop in melanoma. Am J Pathol. 2005 Mar;166(3):823-30. doi: 10.1016/S0002-9440(10)62303-6.
• [14] Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model. J Invest Dermatol. 2003 Jun;120(6):1081-6. doi: 10.1046/j.1523-1747.2003.12252.x.
• [15] CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma. Eur J Clin Invest. 2007 Nov;37(11):887-96. doi: 10.1111/j.1365-2362.2007.01873.x.
• [16] Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003 Aug;2(8):753-63.
• [17] Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. Int J Cancer. 2003 Feb 20;103(5):686-92. doi: 10.1002/ijc.10849.
• [18] Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004 Jun 1;22(11):2092-100. doi: 10.1200/JCO.2004.11.070. Epub 2004 May 3.
• [19] Cerner Multum, Inc. "Australian Product Information.".
• [20] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [21] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [22] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [23] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [24] Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
• [25] Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
• [26] Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
• [27] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [28] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
• [29] Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
• [30] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [31] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [32] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [33] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [34] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [35] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [36] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [37] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [38] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]